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Adverse drug events (ADEs) refer to any injury resulting from the use of a drug [1,2]. 
ADEs can be due to a medication error (intrinsic harm) or an adverse drug reaction (ADR) 
(extrinsic harm) [3-5]. Worldwide many patients suffer from drug related problems such 
as ADEs. Indeed, the report “To Err is Human” by the Institute of Medicine shows that a 
considerable number of people die each year in hospitals partially due to medication related 
harm [6]. In addition, drugs are the leading cause of adverse events in the Medical Practice 
Study [7]. Since then, ADEs have been a subject of intense research. 
A literature review by Krahenbuhl-Melcher et al. conclude that overall in about 6% of 
hospitalized patients ADEs occur, with a wide range among the different studies (0.17–65%), and 
that approximately 50% are considered preventable [8]. The wide range can partly be explained 
by the different ADE detection methods that are used in studies, such as voluntary report of 
ADEs, chart review or computer based monitoring systems to detect ADEs [9,10]. ADEs in 
hospitalized patient do lead to extra costs and prolonged length of stay in the hospital [11-13].
Also in The Netherlands some data is available about the incidents frequency of ADEs. Van 
der Hooft et al. investigated ADR-related hospitalizations and found that in 2001 1.83% and 
in 2003 5.1% of acute hospital admissions are ADR related [14,15]. Leendertse et al. shows 
in their HARM study that of almost 13000 unplanned admissions in the hospital 714 (5.6%) 
are medication related, and that almost half of these admissions are potentially preventable 
[16]. More recently, a prospective chart review shows that more than half of the patients 
admitted to the hospitals are experiencing harm of ADEs, of which most are non-serious, 
non-preventable ADRs [17].
Since a substantial proportion of ADEs can be prevented, it seems logical to focus on the 
preventive aspect in particular. In fact it is better to prevent than to cure. Different methods 
to prevent ADEs are [18,19]:
•	 basic computerized physician order entry (CPOE)
•	 CPOE with clinical decision support system (CDSS)
•	 a clinical pharmacist attending on physician rounds or monitoring 
medication ordering, transcribing and delivery
•	 robots in drug dispensing
•	 “smart” intravenous devices
•	 barcoding of drug and patients 
•	 automated bedside dispensing devices
•	 intravenous admixture units at patient care unit
•	 unit based dosing
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Obviously, each abovementioned method interacts in a particular part of the drug 
distribution chain, from prescribing, dispensing to drug use.
Although a multifaceted approach, such as that Silverman et al.[20] have described for their 
institution seems to be the best option to reduce preventable ADEs, two of these strategies 
have our special interest, namely:
•	 CPOE with CDSS 
•	 clinical pharmacist activities
The review of Krahenbuhl-Melcher et al. shows that medication errors occur at all stages of 
the medication process but most often at the administration stage and in the drug prescription 
process (16.5%, range 13–74% of all errors). CPOE may be in particularly helpful to reduce 
such prescribing errors [8]. Since our institution uses a CPOE already, this intervention 
of reducing prescribing errors is of our interest. Although no randomized control trials 
are performed, there are investigations showing that a reduction in ADEs can be reached 
through the use of CPOE with CDS systems [21-23]. CDS systems can range from basic to 
more advanced systems. Basic CDS systems, for example, include basic dosing guidance 
or drug-drug interaction checking. In contrast, more advanced CDS systems can include 
dosing support for renal insufficiency and guidance for medication-related laboratory testing 
[24]. These advanced CDSS use clinical rules, algorithms, and can search for data available 
in electronic form, such as medication orders, patient characteristics and laboratory values 
[25]. A Dutch study shows that implementation of a CPOE with basic CDSS reduces certain 
types of medication errors (such as dosing errors and administrative and procedural errors) 
but a direct effect on actual patient harm was not demonstrated [26]. 
Hospital pharmacist participation on ward rounds is common in many hospitals and has 
been proven to prevent errors, to lower drug costs and to reduce ADEs in for example 
intensive care and general medicine units [27,28]. Limited human resources may restrict 
pharmacist participation on ward round teams in all of the medical units of a hospital, 
necessitating selection of patients at risk of ADEs [19]. Since we have a special interest in 
clinical pharmacist activities, but we have a limited capacity, we choose to focus on hospital 
pharmacist interventions guided by alerts from CPOE with CDSS.
At our institution, the site where we perform our studies, Leiden University Medical Center, 
a CPOE with basic CDSS is in use since 2003, as one of the first University Medical Centers 
in The Netherlands. This system gives basic drug-drug interaction and drug-dosing alerts 
and can in that way prevent some medication errors [29]. Our hypothesis is that the use of 





ADEs. In addition, hospital pharmacists can interfere to prevent ADEs and, as such, improve 
medication safety. We choose to combine our two strategies of interest to prevent ADEs: 
CDSS for selecting patients at risk of ADEs and hospital pharmacist intervention focused 
on the specific patient at risk instead of participation on ward rounds.
The aim of this thesis is 1) to develop a CDSS with clinical rules to use in the hospital 
pharmacy to select patients with potential ADEs and 2) to investigate the ability of this 
system to select these patients at risk of ADEs and finally 3) to investigate if these potential 
ADEs can be prevented by interventions by the hospital pharmacist. All of these studies 
focus on the hospitalized patient.
This thesis starts with a comprehensive review of the literature in which an overview is 
presented of methods described to prevent ADEs (chapter 2).
The next chapter, chapter 3, describes the development of the CDSS with clinical rules 
aimed to identify patients at risk of ADEs. The system is called Adverse Drug Event Alerting 
System (ADEAS). Besides the development of the system and the definition of the first set 
of clinical rules, the validation of the system and a proof of principle test are described.
In chapter 4 and 5 the newly developed ADEAS is compared with other methods to select 
patients at risk of ADEs. Chapter 4 describes the retrospective and prospective comparison 
of ADEAS with the conventional medication surveillance, using a basic CDSS in the existing 
CPOE. In chapter 5, a limited set of clinical rules from ADEAS and a basic CDSS within 
CPOE is compared with manual pharmacist medication review.
Chapter 6 investigates the extent in which ADEAS based interventions by the hospital 
pharmacist can prevent ADEs in the elderly patient with polypharmacy. This study is 
conducted on 5 hospital wards and ADEs are scored by chart review.
The use of ADEAS with clinical rules in daily hospital pharmacy practice is evaluated in 
chapter 7. This chapter also gives an overview of the rule effectiveness and positive predictive 
value of the clinical rules incorporated in ADEAS.
Finally, in chapter 8, the development of ADEAS and the clinical rules, and the ability of 
the system to select patients at risk of potential ADEs and the ability to prevent these ADEs 
is discussed and put in perspective. This chapter also describes our ideas for future use of 
clinical rules in hospital practice to select risk patients, to prevent ADEs and ultimately to 
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Summary
Adverse drug events (ADEs) are a considerable cause of morbidity and mortality in hospital 
practice. The precise frequency is unknown, but studies give an incidence number ranging 
from 2 until 52 ADEs per 100 patients. There are many different methods for definition, 
causality assessment, severity classification and detection of ADEs which make it difficult 
to compare the different studies. A substantial part (in some studies up to 70%) of ADEs 
can be prevented and it is important to, besides their detection, focus on the prevention 
of these ADEs. In this literature review we give an overview of methods for preventing 
ADEs. There are many different tools with different impact on a particular part of the 
distribution system which has the potential to prevent ADEs. A multifaceted approach is 
needed. Two interesting strategies of prevention, pharmacist participation on ward rounds 
and computerised physician order entry with clinical decision support systems (CDSS), 
are highlighted. Moreover, two promising CDSS are discussed in more detail, namely 








Drug use was the leading cause of adverse events, defined as an injury due to medical 
treatment, in the Medical Practice Study. These so-called Adverse Drug Events (ADEs) were 
accounting for 19.4% of the injuries found in this study [1]. Since then, ADEs have been 
a subject of intense research. There is an enormous amount of data about the incidences, 
detection and costs of ADEs. The precise frequency is unknown, but studies give an incidence 
number ranging from 2 until 52 ADEs per 100 patients [2-13].
The reported incidence figures of ADEs depend partly on different variables, such as 
definition, causality assessment, severity classification and detection methods. The World 
Health Organization (WHO) defines an ADE as ‘any untoward medical occurrence that 
may be present during treatment with a medicine but which does not necessarily have a 
causal relationship with this treatment’ [14]. This definition is often simplified to the more 
straightforward description ‘an injury resulting from the use of a drug’ [3,15].
ADEs can be divided into intrinsic and extrinsic harm. Intrinsic harm is the result of 
the pharmacological properties of the drug itself and is also called adverse drug reaction 
(ADR). Extrinsic harm is related to the manner the drugs are used and is also referred to as 
medication error. Potential ADEs, in contrast to actual ADEs, are medication errors with the 
potential to cause an injury but which do not necessarily cause any injury [15,16]. Different 
classification methods are described in the literature, varying in simplicity from NCC 
MERP medication error index to just mild, moderate and severe [3,5,16-19]. Also varying 
degrees of causality assessment are used [14,20-22]. Methods for the detection of ADEs are 
voluntary report, chart review and computer-based monitoring systems [3,5,12,19,23-26].
All these variables reduce the ability to make generalisations about the data on ADEs and 
make it difficult to compare the studies.
Besides these limitations it is the widespread impression that ADEs in hospitals are costly 
and prolong hospitalisation [6,27,28]. Most adverse events, including ADEs are preventable, 
particularly those due to error or negligence [3]. Theoretically, increasing the knowledge 
on ADEs and its understanding may turn into a higher proportion of ADEs becoming 
preventable.
Since a substantial proportion of ADEs can be prevented it is important to, after the detection, 
focus on the prevention of ADEs. An important step in reducing the incidence of adverse 
events is to identify the patients at highest risk for ADEs. However, in common hospital 
practice it is quite difficult to decide where and how to start. With this in mind, we have 
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reviewed the literature to provide our overview on different useful methods of prevention 
of ADEs. These useful and promising tools for detecting patients at risk for ADEs may 
contribute to an improvement of drug safety.
Methods
A literature search using Pubmed was performed to search for articles published between 
1990 and February 2007. The search was done using the terms ‘adverse drug events’ in 
combination with ‘prevention’ and ‘hospital’. The reference sections of all retrieved articles 
(in English) were manually searched for additional articles. Publications covering ADEs 
encompassing either medication errors and/or adverse drug reactions were included. Papers 
covering outpatient problems were excluded because we focus on hospital prevention of 
ADEs. Rather than exhaustively reviewing the literature on this topic, we selected papers that 
reflect exemplary current practice and suits our abilities and interest in relation to CPOE 
and CDSS and pharmacist ward participation as strategies to prevent ADEs.
Prevention of ADEs
Obviously, ADEs form an important and costly problem in the current health care system. 
As a considerable part of the ADEs are considered preventable, it seems logical to approach 
this problem by focusing on the preventable ADEs. In order to prevent ADEs it is important 
to detect them first. However, it is less clear where and how to start in a complex health 
care environment with a variety of clinical fields, medical professionals, types of patients 
and therapeutic options.
In a system analysis of ADEs, Leape et al. [29] found 16 major system failures as the 
underlying causes of the errors. The most common system failure was in the dissemination 
of drug knowledge, particularly to physicians, accounting for 29% of the errors. Physicians 
made many prescribing errors that appeared to be due to deficiencies of knowledge of the 
drug and how it should be used. These included incorrect doses, dosage forms, dosage 
regimens and routes of administration, as well as errors in the choice of drugs. The systems 
for verifying that the proper drug is delivered in the proper dose sometimes failed in both 
the pharmacy at dispensing and nursing at administrating the drug. A significant cause 
of identity errors was look-alike packing and sound-alike names for drugs. Inadequate 
availability of patient information was associated with 18% of errors. Information about the 
patients’ condition, results of laboratory tests, current medications and recent doses were 
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sometimes not easily accessible when it was needed, leading to prescribing errors as well as 
inappropriate administration of ordered drugs. Pharmacists sometimes lacked information 
about clinical characteristics of patients and results of laboratory tests that would have enabled 
them to intercept an improper order. Other system failures were order transcription, allergy 
defence, medication order tracking and interservice communication [29]. Bates et al. [30] 
proposed a risk stratification model for patients likely to experience an ADE using a cohort 
analysis and a case-control study. However, almost none of the proposed ‘risk factors’, such 
as age, multiple drug therapy and impaired renal function, were actually associated with 
a substantially elevated risk of developing an ADE. No major drug class was responsible 
for a disproportionate share of the ADEs, with the possible exception of analgesics. They 
concluded that rather than targeting patients at high risk of experiencing an ADE, prevention 
strategies should focus on improving medication systems [30], for example implementing a 
patient safety program [30-32] or performing risk assessment with multidisciplinary teams 
[33]. In a paediatric setting, Fortescue et al. [34] analysed 10 medication error prevention 
strategies for their potential effectiveness in reducing both overall error rates and potentially 
harmful error rates. These10 strategies included: (1) basic computerised physician order 
entry (CPOE); (2) CPOE with clinical decision support systems (CDSS) including checks 
of drug ordering and patient factors; (3) a clinical pharmacist on physician rounds or 
monitoring medication ordering, transcribing and delivery; (4) changes in communication; 
(5) computerised medication administration records; (6) robots in drug dispensing; (7) 
‘smart’ intravenous devices for performing dilutions; (8) barcoding of drugs and patients; 
(9) automated bedside dispensing devices and (10) unit-based dosing. They found that three 
interventions might have prevented 98.5% of all potentially harmful errors being CPOE with 
CDSS, ward-based clinical pharmacists monitoring ordering, transcribing and administering 
and improved communication among physicians, nurses and pharmacists [34].
A study from Evans et al. [35] was designed to identify inpatient risk factors for ADEs. 
Conditional logistic regression was used to analyse all pharmacist-verified ADEs by 
therapeutic class of drugs and severity during a 10-year study period in a 520-bed teaching 
hospital. Each case patient was matched with up to 16 control patients. They found four 
classes of drugs causing the majority of the ADEs: analgesics, anti-infectives, cardiovascular 
agents and anti-coagulants. They also showed that female gender was a uniformly significant 
risk factor for ADEs, while age was not. Creatinine clearance was a prominent risk factor 
only in the cardiovascular drug category. Increased dose, number of co morbidities and 
parenteral routes of administration were found to be a significant risk factor for ADE in 
nearly every drug category. They conclude that the four high-risk drug classes should be 
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closely monitored based on patient characteristics (gender, age, weight, creatinine clearance, 
number of comorbidities) and drug administration (dosage, administration route, number 
of concomitant drugs) [35].
Clearly, there are many different tools which have the potential to prevent ADEs but with 
different impact. Each tool has its impact on a particular part of the drug distribution system, 
for example barcode scanning of drugs and patients will only prevent administration errors 
and not other kinds of ADEs. Thus, a multifaceted approach, such as that Silverman et al. [36] 
has described for their institution, seems to be the best option to reduce preventable ADEs.
Two strategies of such a multifaceted approach to prevent ADEs we have special interests 
in and will be highlighted. These interventions are: (1) pharmacists participation on ward 
rounds and (2) CPOE with CDSS. Two of these CDSS we are working on as well and are 
discussed in more detail, namely (A) computer-based monitoring system with alerts and 
(B) linking laboratory and pharmacy information systems.
Pharmacist participating on ward rounds
Fortescue et al. [34] proposed clinical pharmacists on ward rounds as a potential strategy 
to reduce ADEs. Leape et al. [37] conducted a controlled clinical trial to estimate the effect 
of pharmacist participation on medical rounds in the ICU on the rate of preventable ADEs 
caused by medication ordering errors. During a 6 month period in a large urban teaching 
hospital a senior pharmacist participated on rounds with the ICU team and remained in the 
ICU for consultation in the morning and was available on call throughout the day. The rate 
of preventable prescribing ADEs decreased by 66% from 10.4 per 1000 patient days (95% CI, 
7–14) before the intervention to 3.5 (95% CI, 1–5; p < 0.001) after the intervention. In another 
unit, which served as a control, the rate was essentially unchanged during the same period. 
The pharmacist made 366 recommendations related to drug ordering, of which 362 (99%) 
were accepted by physicians. The recommendations varied from clarification or correction 
of the medication order, provision of drug information to recommendation of alternative 
therapy and identification of drug–drug interactions [37]. Similarly, Kucukarslan et al. [38] 
studied during a 3 month period the effect of pharmacists on rounding teams in a general 
medicine unit. The services of the clinical pharmacist included rounding, documenting 
pharmacotherapy history and providing discharge counselling. The rate of preventable 
ADEs was reduced by 78%, from 26.5 per 1000 hospital days to 5.7 per 1000 hospital days. 
They documented 150 interventions, of which 147 were accepted by the team. The most 
common interventions were dosing-related changes and recommendations to add a drug to 
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therapy [38]. A systematic review of Kaboli et al. [39] evaluated the published literature on 
the effects of clinical pharmacist interventions in controlled trials in hospitalised patients. In 
36 studies, three different types of clinical pharmacist services were reviewed: (1) patient care 
unit pharmacist participation on rounds (10 studies); (2) admission or discharge medication 
reconciliation (11 studies) and (3) drug class-specific pharmacist services (i.e. inpatient anti-
coagulation services, antibiotic therapy and infectious disease counselling and therapeutic 
drug monitoring services; 15 studies). Different outcome measures were used. For example 
7 of 12 studies reported a reduction of ADEs, ADRs or medication errors and 5 reported no 
differences. Hospital length of stay was reduced in 9 of 17 trials and readmission rates, ICU 
transfers, test use and costs were either reduced or not affected. Mortality was evaluated in 
eight trials. One showed a significant reduction. Of the other seven studies, three demonstrated 
lower mortality and four demonstrated higher mortality in the intervention group, but these 
differences were not significant. The overall conclusion was that the addition of clinical 
pharmacist services in the care of the inpatients generally resulted in improved care, with 
no evidence of harm [39]. Finally, in a 84 beds paediatric academic setting, Wang et al. [40] 
quantified the harmful medication errors and ADEs that occurred during a 3 month period 
and judged whether or not these were intercepted by the clinical pharmacist system and 
if not whether it would have been captured by CPOE. They found 865 medication errors, 
including 687 non harmful medication errors, 162 near misses and 16 preventable ADEs, 
and also 36 non preventable ADEs. Of all potential harmful medication errors 54% were 
intercepted by the clinical pharmacist system. This included 78% of prescribing errors but 
none of the administration errors. An idealised paediatric CPOE with CDSS could capture 
additional prescribing errors (78% vs. 93%; p = 0.002), but not administration errors [40].
The positive effect of pharmacist participation on rounds on improving medication safety is 
obvious; however, data on cost effectiveness are currently lacking. In the study of Leape et al. 
the total commitment of the clinical pharmacist was approximately half of the pharmacist’s 
time [37]. This means that having clinical pharmacists available on all hospital wards may 
be unrealistic also because of shortage in pharmacists in many countries.
CPOE with CDSS
One intervention that has our interest and has substantial potential for improving the 
medication ordering process is CPOE in which physicians write orders online [41,42]. It has 
been recommended by the Leapfrog group as one of the first leaps to be implemented as a major 
step to improve patient safety in the USA [43]. CPOE ensures complete, legible, standardised 
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and clear orders. CDSS are built into almost all CPOE systems to varying degrees and have 
the ability to improve patient safety. Basic clinical decision support provides computerised 
advice regarding drug dose, routes and frequencies, and more sophisticated CDSS can perform 
drug allergy checks, drug-laboratory value checks and drug–drug interaction checks and can 
provide reminders about corollary orders or drug guidelines [44-46]. In his systematic review 
Kaushal et al. [44] evaluated five studies regarding CPOE with CDSS. Of these studies two 
demonstrated a marked decrease in the serious medication error rate, one an improvement 
in corollary orders, one a prescribing improvement in dose and frequency of drugs and one 
an improvement in dose and frequency prescription of nephrotoxic drugs. For example, two 
studies from Bates et al. [47,48] showed a 55% and 86% decrease in preventable and non-
intercepted potential ADEs, respectively. The first study showed a decline from 10.7 events per 
1000 patient days to 4.68 events (p = 0.01). The rate of ordering errors decreased 19% overall, 
the number of transcription errors fell by 84% and the rates of dispensing and administration 
errors fell by 68% and 59%, respectively [47]. The event rate in the second study fell from 
7.6 per 1000 patient days to 7.3 per 1000 patient days after implementing CPOE and further 
to 1.1 per 1000 patient days after improving drug allergy checking, potassium ordering and 
drug–drug interaction checking [48]. A more recent study in the ICU, conducted during a 
5 week period, comparing two paper-based units with one unit with CPOE, found a relative 
reduction of 86.7% for all types of errors associated with medication ordering. The incidence 
of non-intercepted potential ADEs and ADEs together was significantly lower in de CPOE 
unit (n = 23) compared with the paper-based unit (n = 60) [49]. However, there have also 
been some negative reports on CPOE. Han et al. found an unexpected increase in mortality 
coincident with CPOE implementation [50]. Moreover, Koppel et al. [51] reported that a widely 
used CPOE system facilitated 22 types of medication error risks, mainly systems integration 
failure and human-machine interface flaws, and as Wang et al. [40] judged, CPOE captures 
mostly prescribing and transcription errors, but not administration errors.
Overall, CPOE has many benefits beyond medication safety and is a useful tool to prevent 
ADEs. It is good to realize that not every CPOE (with CDSS) is the same and that there are 
important differences between the systems used in different countries. Overall, it is here to 
stay, but needs continuous monitoring and fixing [52].
Computer-based monitoring system with alerts
One example of CPOE with CDSS to prevent ADEs is the use of computer-based monitoring 
systems, also called clinical event monitoring systems or clinical event monitors. These 
systems can use any data available in electronic form to detect adverse drug events. These 
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can be administrative data, like coded data (ICD-9-CM), free text trigger words, drug 
prescription, or multiple data like combination of sources using queries, rules or algorithms 
[19,23,24,53]. We focus on systems that monitor clinical laboratory data, demographic 
patient data and physician orders within a CPOE system by using defined clinical rules. 
These clinical rules or algorithms are based on identifiers searching for specific medication 
orders, patient characteristics and/or laboratory values [5,25,54,55].
Raschke et al. [54] developed a computer alert system to correct errors that might lead to 
ADEs and to detect ADEs before maximum injury occurs. In a prospective case series 37 
drug-specific ADEs were targeted. During the last 6 months of 1997 the alert system fired 
1116 times and 596 (53%) were true-positive alerts (defined as in which the physician wrote 
orders consistent with the alert recommendation). The alerts identified opportunities to 
prevent patient injury secondary to ADEs at a rate of 64 per 1000 admissions [54]. Likewise, 
Silverman et al. [55] used a computer-based detection system with rules that identify 
actionable events (excluded identification of ADE after it has occurred). In 3 different 
periods they used 58 rules and performed 169, 452 and 792 interventions based on these 
rules respectively. The rules were continually assessed by evaluating the positive predicted 
value. Of these interventions by pharmacists, 133 (78.7%), 411 (90.9%) and 730 (92.2%) 
were accepted by the physician in each period, respectively. The most efficient rules in 
terms of intervention were a quinidine level above 5 mg/dl and a theophylline level above 20 
mg/dl [55]. It is essential that the CDSS provide the user with relevant guidance regarding 
prescribing and monitoring decisions without overwhelming the user with irrelevant alerts; 
if too many low-level alerts are delivered, prescribers may disregard important warning 
messages [56]. A problem that might occur with CDSS is ‘alert fatigue’. In their review, 
Van der Sijs et al. [56] mention that in 49% to 96% of cases, drug safety alerts in CPOE are 
overridden by clinicians. They warn for error-producing conditions of the alert system, 
like low specificity, low sensitivity, unclear information content, unnecessary workflow 
disruptions and unsafe and inefficient handling. One explanation may be that medication 
control is one of the tasks of the complex function of the physician, whereas medication 
control is the core business of the pharmacist. Therefore a broader range of warnings can 
still be displayed to the pharmacist, for example after prescribing but before dispensing.
Linking laboratory and pharmacy information systems
Many of the clinical rules used in computer-based monitoring systems consist of a 
combination of drug and laboratory algorithms. Laboratory and pharmacy functions are 
closely related. Drug choice and dosing often depend on laboratory information such as 
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therapeutic drug levels and biochemical and other physiologic parameters. Despite this 
relation between laboratory and pharmacy, connection between their information systems 
is often suboptimal or non-existent [57]. ADEs that may be prevented by use of such a CDSS 
are for example wrong dosing of drugs which are eliminated by the kidney in patients with 
impaired renal function [58,59], prescribing potassium to patients despite high plasma 
potassium level [60] and lack of monitoring at initiation of drug therapy [61]. Several studies 
have demonstrated that drug- laboratory combinations are one of the best tools for identifying 
(potential) ADEs [5,19,25,62]. Schiff et al. [57] describe in their review 10 ways in which 
laboratory and pharmacy data can be related to improve patient care. Their knowledge-
based rules are for example linking laboratory findings with drug selection (indication or 
contraindication), with drug dosing, drug use with laboratory monitoring for toxicity and 
also drug use and interference with laboratory measurements. The linking between tests 
and treatments can be retrospective, linking downloaded laboratory and pharmacy files, or 
real-time via CPOE with CDSS [57].
Information technology can reduce the frequency of ADEs. The main classes of strategies 
for this prevention include tools that can improve communication, make knowledge more 
readily accessible, require key pieces of information, perform checks in real time, assist with 
monitoring and provide decision support. However in today’s systems, many important 
warnings are ignored and there are too many unimportant warnings. Thus, pre-screening 
by the pharmacist can be useful [45,63].
Conclusion
ADEs in hospital practice cause considerable morbidity and even mortality albeit its precise 
frequency is yet unknown. Since a substantial proportion of the detected ADEs can be 
prevented we find it important to focus on the prevention of ADEs. It is suggested to follow 
a systems approach, involving multiple strategies, such as CPOE with sophisticated CDSS 
and patient-oriented pharmacy services, to adequately encounter the problem of ADEs in 
hospital settings. Linking pharmacy and laboratory data is a good way to start. Information 
technology can be very helpful to reach this goal.
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Introduction: Adverse drug events (ADEs) are frequent and pose an important risk for 
patients treated with drugs. Fortunately, a substantial part of ADEs is preventable, and 
computerised physician order entry with a sophisticated clinical decision support system 
may be used to reach this goal.
Objective: To develop a new system that could improve the quality of medication surveillance. 
The system should focus on detecting patients at risk of an ADE by combining data from 
the hospital information system and computerized physician order entry (drug prescription 
data, drug-drug interaction alerts, clinical chemical laboratory parameters, demographic 
features), using clinical rules.
Methods: The clinical rules were formulated in a multidisciplinary team based on seven risk 
categories. The new system was composed in a guideline-based decision support framework 
consisting of both a guideline development module and a decision support module. A total 
of 121 clinical rules were built into the system. Validation of the system and a proof of 
principle test were performed.
Results: The adverse drug event alerting system (ADEAS) was developed and validated 
successfully. The proof of principle test showed that ADEAS has potential usefulness. ADEAS 
generated alerts and detected additional potential risk situations, which were not generated 
by conventional medication surveillance.
Conclusion: We developed a pharmacy decision support system ADEAS that focusses on 
the detection of situations prone to lead to an ADE and might help clinicians to take timely 










Adverse drug events (ADEs) and medication errors pose a serious risk for hospitalised 
patients. A recent review shows that medication errors occur in about 5% (range 0.038%–
56.1%) of all episodes of drug administration and that ADEs occur in about 6% (range 
0.17%–65%) of hospitalised patients. About 46% (range 15%–90%) of ADEs, mainly those 
resulting from medication errors, appear to be preventable [1]. A reasonable approach to 
increase patient’s safety is to focus on the prevention of ADEs by identifying patients at 
highest risk for development of an ADE. Computerised physician order entry (CPOE) 
combined with a sophisticated clinical decision support system (CDSS), including usage of 
electronic pharmacy and laboratory data, can be used to detect those patients at risk of an 
ADE [1-3]. Potential risky situations can be defined in clinical rules [4,5]. This approach 
would permit physicians and pharmacists to take corrective actions before harm occurs.
In our hospital, the CPOE system in use provides online drug–drug interaction checks 
and drug-dosing checks but is not integrated with a sophisticated CDSS [6]. This current 
surveillance system has some limitations: 1) there is no possibility to adapt medication 
surveillance to categories of patients and/or to medical specialities, [7] 2) the system does not 
take into account relevant laboratory values, and 3) most alerts are of low clinical relevance 
with the consequence of ‘alert fatigue’ [8].
Given these limitations and the wish for more clinical pharmacy activities, we aimed to 
develop a new pharmacy decision support system that could improve the quality of our 
medication surveillance. The system should focus on patients at risk of an ADE by combining 
more data available from the hospital information system and CPOE, using clinical rules.
In this context, we describe the development of our computerised alert system, adverse drug 
event alerting system (ADEAS).
Methods
Setting
Leiden University Medical Center is a university hospital in Leiden, The Netherlands. The 
hospital information system, Mirador (iSOFT Nederland, Leiden, The Netherlands), contains 
integrated patient-specific data, including demographics, laboratory results, discharge letters, 
diagnosis, surgery reports, radiology reports and pharmacy orders. The CPOE system in use, 
Medicator (iSOFT Nederland), provides online, during prescribing, drug–drug interaction 
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checks and drug-dosing checks but is not integrated with a sophisticated CDSS [6]. The 
safety alerts in the CPOE system are based on a national drug information database, the 
G-standard (Z-Index, The Hague, The Netherlands). The G-standard contains information 
about all drugs (approved and none approved) available in The Netherlands, and the majority 
of Dutch pharmacy information systems use this database to support different processes 
such as medication surveillance.
Current procedure of our conventional medication surveillance is that hospital pharmacists 
perform daily retrospective checks of the drug–drug interaction and drug-dosing alerts 
overridden by the physician during prescribing. The hospital pharmacist selects potentially 
clinical relevant alerts to discuss with the prescribing physician by phone. Additional dosing 
advice is given following therapeutic drug monitoring results.
Description of the system
The development process of the new system can be subdivided into four phases: 1) the 
definition of the contents of the clinical rules, 2) the development of expert system itself 
(ADEAS), 3) building of clinical rules into ADEAS and 4) technical validation (see flowchart, 
Figure 3.1).
Figure 3.1 Flowchart development ADEAS / clinical rules. 
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Definition of clinical rules
First, we have put together a multidisciplinary team including a pharmacist, a hospital phar-
macist, an internal medicine specialist and a hospital pharmacist-clinical pharmacologist, 
to discuss the contents of the clinical rules. We used the Dutch national formulary 
(Farmacotherapeutisch Kompas, College voor zorgverzekeringen, Diemen, The Netherlands) 
and local medical reference books (e.g., hospital antibiotics formulary) to identify drugs or 
drug classes suitable for use in a clinical rule. From a drug perspective, we used seven risk 
categories to formulate the clinical rules (Table 3.1). For each drug or drug class, the seven 
risk categories were discussed in the multidisciplinary team and finally resulted in agreement 
and definition of various clinical rules. An example of a rule for each risk category is given 
in Table 3.1. We did not formulate clinical rules for anticancer drugs because ADEs related 
to these agents are frequent, well recognised, intensively monitored but difficult to fully 
prevent. Moreover, for prescribing anticancer drug regimens, the CPOE system already 
assists the physician by applying chemotherapy prescription protocols [7]. Overall, we 
defined about 300 clinical rules.
Table 3.1 7 risk categories which are used to define clinical rules from a drug perspective
1 Linking biochemical laboratory values with the initiation of a drug
example: patient with aminoglycoside or vancomycin and plasma creatinine unknown last 7 days before 
start
2 Linking biochemical laboratory values or therapeutic drug monitoring values with the ongoing use 
of a drug
example: patient with SSRI and platelets < 100 x 109/L or platelets drop > 25%
3 Linking the use of a drug with the non-use of another drug the latter indicated for the prevention 
of an ADE
example: patient with opioid receptor agonist and no laxative within 2 days after the prescription of the 
opioid receptor agonist
4 Medication used to treat an ADE
example: patient with ACE inhibitor and codeine or anti-cough medication
5 The history of our currently used medication surveillance system fine-tuned to risk-patients
example: patient (> 60 yr) with low dose aspirin or NSAID (except COX-2 inhibitor) and CHF without ulcer 
protection
6 Alert from inspectorate authorities such as EMEA or company regarding an ADE and/or special 
considerations for use from product label
example: patient with azathioprine (alert from Dutch inspectorate authority that dose check related to 
patient weight is required for this drug)
7 Common medication errors, including alerts from the Dutch CMR (Central Medication Error Registration)
example: patient with methotrexate once daily instead of once weekly
ADE, adverse drug event; COX, cyclooxygenase; CHF, congestive heart failure; EMEA, European Medicines 
Agency; SSRI, Selective serotonin reuptake inhibitor.
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Development of the CDSS (ADEAS)
Second, we built the expert system itself. ADEAS was composed in Gaston (Medecs, 
Eindhoven, The Netherlands), a guideline-based decision support framework consisting of 
both a guideline development module and a decision support module [9,10]. The guideline 
development module consists of a Task Network Module [11] that describes the structure 
(‘logic’ or ‘flow’) of the guideline by means of a set of primitives (such as observations, 
decisions, actions) and domain-specific knowledge in the form of one or more terminologies. 
We defined the following terminologies: drug, laboratory values, drug–drug interactions 
and patient characteristics. The data for the ‘drug’ and ‘drug–drug interaction’ sections were 
imported from the national drug information database, the G-standard. The data regarding 
laboratory values and patient characteristics were imported from the hospital information 
systems, Glims (MIPS Diagnostics Intelligence, Clinisys, UK) and Mirador. The information 
about the drug use of a specific patient was imported from the CPOE, Medicator (Figure 
3.1, grey box).
The decision support module was used to link Gaston with our hospital information system 
for importing the required information and to execute the clinical rules. Gaston was originally 
designed as a CDSS, but we wanted to use ADEAS as a pharmacy decision support system 
instead, thus technical adaptations were made to the reporting technology.
Building clinical rules into ADEAS
The primitives and terminologies were combined and used to create and build the clinical 
rules into the system (Figure 3.2). The items were dragged to the desired field (positive or 
negative preferences). Per terminology item, sub items such as dosages or administration 
route for a drug could be added. Most clinical rules consisted of simple observations of one 
or more positive and/or negative term preferences, for example, a drug prescription and 
the presence of a laboratory value (Figure 3.2) or a drug prescription and the absence of 
a laboratory value. More complicated clinical rules were built as a flowchart (Figure 3.3).
Of the about 300 clinical rules defined, we finally incorporated 121 clinical rules in the 
system (Appendix). These clinical rules were chosen because they were considered most 
relevant to our hospital practice.
Validation
After building the clinical rules into ADEAS, we performed a validation to establish the 
technical correctness of the system. It is necessary to investigate that the system adequately 









system should not generate false positive or false negative alerts. The correct performance 
of the system depends on the way the clinical rules are built in ADEAS, thus in the way the 
primitives and terminologies are used to create the rule or flowchart. Looking at our rules, 
we established that we had used 45 different technical ways of building and describing a 
rule in ADEAS, for example, rules consisting of only a positive term ‘drug’, rules consisting 
of a positive term ‘drug’ and a positive term ‘laboratory value, creatinine value’, individual 
flowcharts, rules consisting of a positive term ‘drug’ and a dosage limitation, etc. We divided 
all rules in the 45 different groups, and instead of validating each separate clinical rule, we 
selected one representative rule of each group for validation. The validation of that rule 
was representative of the rest of the clinical rules in the group. We considered it allowed to 
perform the validation in this way because ADEAS imports its data from already validated 
subsystems (Mirador, Medicator, etc). We used three different methods for the validation: 
A) use of dummy patients, B) in an off-line test setting, and C) behind-the-scene testing.
Figure 3.2 Adverse drug event alerting system (ADEAS) clinical rule consisting of two positive term 
preferences: drug prescription of ciprofloxacin is known and creatinine clearance is < 25 ml/min or 
plasma creatinine exceeding 250 µmol/l. 
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A. Based on the content of the defined clinical rules, we entered medication orders in the 
CPOE for non-existing (dummy) patients. These dummy medication orders should either 
generate an alert (positive control: e.g., prednisolon and ibuprofen in an 80-year-old patient 
without a proton pump inhibitor) or not generate an alert (negative control: e.g., prednisolon 
and ibuprofen and pantoprazole in an 80-year-old patient). The output of ADEAS was 
compared with the intended output based on the entered medication combinations. Since 
dummy patients do not have clinical laboratory data in their hospital information system, 
this way of validation is only suitable for clinical rules based on medication data alone.
B. Clinical rules based on laboratory values were tested in existing patients in an off-line 
test setting. We selected patients with required laboratory values and entered medication 
in an off-line setting in the same way as described above. Again, we compared the output 
of ADEAS with the expected output based on the combination of entered medication and 
laboratory values.
Figure 3.3 Adverse drug event alerting system (ADEAS) clinical rule consisting of a flowchart 
(combination of primitives and domain-specific terms). Every primitive contains one or more positive 









C. Finally, in the behind-the-scene validation method, ADEAS was run in the central 
pharmacy, behind the scene, on a selected group of clinically admitted patients. The electronic 
patient file of the patient was checked manually to compare the output of ADEAS with the 
expected output and to search for false negative results.
During the validation, the structure of the clinical rules was changed and adapted until 
testing resulted in no more false negative or false positive results. We did not calculate the 
sensitivity and specificity in numbers because we considered the technical validation as 
part of the development.
Study design
Following the development of ADEAS, we performed a proof of principle test (see flowchart, 
Figure 3.1). This test was performed to establish the potential clinical usefulness of ADEAS. 
For the test, we activated 13 different clinical rules, at least one rule of each risk category 
(Table 3.2). We choose these 13 clinical rules for two reasons: 1) the situations described in 
Table 3.2 Results proof of principle study of ADEAS with 13 clinical rules active processing during 
3 days
Clinical rule No. patients 
Patient with aminoglycoside or vancomycin and plasma creatinine unknown last 7 days 
before start
0 
Patient with SSRI and platelets < 100 x 109/l or platelet drop > 25% 0 
Patient with nitrofurantoine and CL < 50 ml/min* 0 
Patient with opioid receptor agonist and no laxative within 2 days after prescription of 
opioid receptor agonist
45 
Patient with ACE inhibitor and codeine or anti-cough medication 1 
Patient (> 70 yr) with low dose aspirin or NSAID (except COX-2 inhibitor) or patient (> 60 
yr) with low dose aspirin or NSAID (except COX-2 inhibitor) and additional risk factor for 
bleeding without ulcer protection
17 
Patient with azathioprine 6 
Patient with 5-HT1 serotonin receptor agonist or ergotamine 1 
Patient with plasma creatinine > 150 µmol/l 36 
Patient with CL < 50 ml/min* 21 
Patient with plasma creatinine rise > 50% 11 
Patient with plasma creatinine rise > 50 µmol/l 10
Patient with CL decline > 50%* 1 
* CL, creatinine clearance.
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these rules are highly prevalent and 2) the situations described present relatively high-risk 
situations prone to lead to patient harm [12-14]. During 3 days, ADEAS was processing 
every night collecting new patients and data from the electronic patient file of all admitted 
patients to the hospital at that time. The amount and contents of the alerts generated with 
ADEAS was compared retrospectively with the alerts and interventions that resulted from 
the conventional medication surveillance in the same period. This was done to assess the 
potential additional value of ADEAS compared with our current medication surveillance. 
The positive predictive value of the clinical rules was not calculated because we did not 
register the actions made by the pharmacist or physician following an alert from ADEAS.
Results
During the three days of the proof of principle test, on average, 400 patients were admitted 
to the hospital per day. ADEAS, with 13 active clinical rules, generated 149 alerts covering 
116 patients (Table 3.2). Of these alerts, 20 were related to a declined renal function. In the 
same period, the conventional medication surveillance system generated 308 alerts (on 
average 100 alerts per day) in 240 different patients. In only 6% (n = 20) of these alerts, the 
pharmacist retrospectively contacted the physician to give additional advice about separate 
administration of drugs (n = 10), ECG monitoring (n = 4), therapeutic drug monitoring 
(n = 5) or adding additional medication (n = 1). The alerts generated with ADEAS 
regarding a declined renal function were not generated as safety alerts within the CPOE. 
The conventional medication surveillance generated drug–drug interaction alerts between 
a non-steroidal anti-inflammatory drug and a corticosteroid, even when a prescription 
of a proton pump inhibitor (PPI) was present. ADEAS only selected the situations a PPI 
was absent. ADEAS also selected situations in which low-dose aspirin was prescribed to 
patients > 70 years of age. The conventional medication surveillance only selected these 
situations when a drug–drug interaction with low-dose aspirin was present in a patient with 
that age.
Discussion
We developed a pharmacy decision support system (ADEAS) that is able to electronically 
detect patients with potential riskful situations of an ADE described in clinical rules. 
Combined data from the CPOE, the hospital information system and the national drug 









The definition of the clinical rules was done by a multidisciplinary team using a national 
formulary. We applied a structured method using seven risk categories to define the clinical 
rules. This method resulted in a large set of clinical rules with a wide clinical coverage. 
The technical validation revealed that the system is able to correctly identify patients in 
situations described in the clinical rules. The proof of principle test showed that ADEAS 
has clinical useful potential.
A strength of ADEAS is that it combines data from different databases available in the 
hospital. Especially, the possibility to use laboratory data (e.g., declined renal function) is 
of large added value [15]. Other areas such as microbiology and medical diagnosis were 
not included because coded data on that area were not available. The result of the proof 
of principle test showed that ADEAS generated different kinds of alert compared with the 
conventional medication surveillance. On the other hand, not all safety alerts from the 
G-standard within the CPOE were built in ADEAS. This means that for now, the two systems 
are both used next to each other until further development takes place.
Originally, most studies used clinical rules as triggers to identify ADEs that have already 
occurred. In these studies, commonly used triggers include a toxic serum drug level or a 
prescription of an antidote [15-21]. A limitation of these rules is that they identify ADEs 
that already resulted in harm and thus lack the opportunity to prevent harm. ADEAS agrees 
with the current idea to use clinical rules to detect patients at risk of an ADE. Like others, 
ADEAS selects evolving unsafe situations in which generated alerts permit physicians or 
pharmacists to make timely corrective interventions [4,5,12,14,22]. Silverman et al. showed 
that after modification of their clinical rules from detecting actual ADEs to identifying 
potential ADEs, the total number of interventions by the pharmacists increased, and the 
rules became more efficient [23].
There are some limitations of ADEAS. First, the development of the system itself was time-
consuming and needed a large amount of technical support. Currently available CPOE 
systems on the Dutch market are not integrated with CDSS, and of the few CDSS available, 
such as Gaston, none matches the exact specifications essential for the application as 
described here. This was the reason technical adaptations were necessary. This might make 
it difficult to replicate for other institutions, but currently, two other university hospitals 
in The Netherlands have started using this system. Although similar computerised alert 
systems were developed in the United States [24] and Europe [25], they are not available in 
The Netherlands. There is very limited experience with the development of such systems 
among Dutch hospital pharmacies, and we are one of the first to report so.
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Second, ADEAS is developed as a pharmacy decision support system and not as a CDSS 
within the CPOE. The alerts generated by the system go to the pharmacist and not directly 
to the prescribing physician. The reason for this is that we want to use ADEAS as a tool 
for the hospital pharmacist for more clinical ward-based activities. Following an alert from 
ADEAS, the pharmacist can visit the ward and consult with the physician to discuss the 
clinical relevance of the potential ADE situation. Also, we believe that pre-screening of 
safety alerts by the pharmacist is useful to prevent alert fatigue with the physician [24,26]. 
A review from Van der Sijs et al. showed that in 49%–96% of all cases, physicians ignore 
safety alerts. This can lead to error-producing situations; the physician does not recognise 
a really clinical relevant and important alert [8]. Medication control is the core business of 
the pharmacist,  and it is suggested that the prescribers’ knowledge of potential clinically 
relevant drug–drug interactions is generally poor [27]. Especially in the starting period 
when the clinical rules might need adaptation, it is useful to see the alerts in the pharmacy. 
In the future, some alerts might be better situated as online alerts for the physician when 
immediately action is necessary.
Finally, in this study, we did not establish the clinical relevance and positive predictive value 
of the rules. This is important and will be done in the future. In this light, it may be more 
efficient to start with a small set of clinical rules covering a specific clinical area (e.g., drug 
dosing in patients with a declined renal function) [12,14] instead of a large set, as we did.
In conclusion, we succeeded in developing a pharmacy decision support system ADEAS, 
which is able to electronically detect patients at risk of an ADE and might help clinicians to 
take timely corrective interventions and thereby prevent patient harm.
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Abstract
Background: Adverse drug events (ADEs) are an important problem in hospital practice. 
Computerized physician order entry (CPOE) and clinical decision support systems (CDSS) are 
useful tools in the prevention of ADEs. In The Netherlands there are some basic CDSS within 
CPOE systems, but there is not much experience with sophisticated systems. We have recently 
developed a more advanced CDSS, a computerized adverse drug event alerting system (ADEAS).
Objective: The aim of the study was to compare the newly developed ADEAS, which uses 
a set of clinical rules, with the conventional medication surveillance, a basic CDSS within a 
CPOE, to assess its additional value in detecting patients with a potential ADE.
Setting: Leiden University Medical Center (LUMC), a university hospital in Leiden, The 
Netherlands.
Design: Two studies were carried out; one retrospective and one prospective. The retrospective 
comparison of ADEAS with conventional medication surveillance was conducted on all 
patients admitted to the hospital (except intensive care unit patients) during a 1-month period 
(15 November – 15 December 2006). A prospective comparison of both systems was performed 
during a 6-month period (May – October 2007) on one general internal medicine ward.
Measurements: The endpoint was the total number of alerts and content of alerts generated 
by both methods. In the prospective study we also focused on the number of unique alerts 
and interventions by the hospital pharmacist following the alerts.
Results: In the retrospective study, ADEAS generated 2010 alerts compared with 2322 
generated by the conventional method. In the prospective study, 248 and 177 alerts were 
generated by ADEAS and the conventional method, respectively. The number of unique 
alerts was 85 (of which 72 were considered true positive alerts) and 136, respectively. The 
hospital pharmacist made 14 (19.4%) interventions following a true positive alert with 
ADEAS and 5 (3.7%) with the conventional method. The contents of alerts generated by 
ADEAS were different to the safety alerts generated by conventional medication surveillance. 
The conventional medication surveillance generated safety alerts regarding drug–drug 
interactions and drug-overdosing. ADEAS generated alerts regarding declined renal function 
or other laboratory abnormalities and absence of essential concurrent medication.
Conclusions: Compared with our conventional medication surveillance, the computerized 
alert system ADEAS selected different patients at risk of an ADE. This makes ADEAS in 
our hospital of additional value to the hospital pharmacist as a suitable tool in reducing the 











A substantial number of hospitalized patients experience harm due to medication. Different 
studies report that adverse drug events (ADEs) occur at a wide range of rates (0.17–65%) 
in hospitalized patients, and that approximately 50% are considered preventable [1]. In 
the literature, it is suggested that computerized physician order entry (CPOE) and clinical 
decision support systems (CDSS) can be important tools to facilitate the prevention of ADEs 
[2,3]. CPOE ensures complete, legible, standardized and clear orders, and CDSS are built 
into almost all CPOE systems to varying degrees. They can provide computerized advice, 
basic alerts regarding drug–drug interaction or more sophisticated alerts regarding drug-
laboratory value checks. As far back as 1991, Classen et al. [4] described the development 
of a computerized system using algorithms or clinical rules to detect and characterize ADEs 
in hospital patients. In addition, Jha et al. [5] described that computer-based monitoring is 
an efficient way to identify ADEs compared with traditional detection methods. Later, such 
computerized alert systems were also used to prevent ADEs. Raschke et al. [6] developed 
a computer alert system to correct errors that might lead to ADEs and detect ADEs before 
maximum injury occurs. Also, Silverman et al. [7] used a computer-based system to prevent 
ADEs with clinical rules. They modified the rules used by Jha et al. [5] to include rules that 
identify actionable events and exclude rules that identify an ADE after it occurs (e.g. the 
ordering of an antidote) [7]. Meanwhile, different studies have shown that such CDSS within 
CPOE are successful strategies for reducing ADEs and medication errors [8-12].
In our hospital, the CPOE system in use provides online drug–drug interaction checks and 
drug-overdosing checks, but is not integrated with a sophisticated CDSS [13]. This current 
surveillance system has some limitations: 1) there is no possibility to adapt medication 
surveillance to categories of patients and/or to medical specialties; [14] 2) the system does 
not take into account relevant laboratory values; and 3) most alerts are of low clinical 
relevance, with the consequence of ‘alert fatigue’ [15]. Moreover, a recent Dutch study 
showed that implementation of such a CPOE with basic CDSS does reduce certain types 
of medication errors but not therapeutic errors and preventable ADEs [16]. Given these 
limitations, we decided to develop a new pharmacy decision support system that could 
improve the quality of our medication surveillance. The new system should both improve 
the specificity of the alerts compared with the current system and cover the lacking alerts, 
e.g. regarding declined renal function. As a result we have developed a computerized adverse 
drug event alerting system (ADEAS) with which patients at risk of an ADE can be detected 
electronically by combining more data available from the hospital information system and 
CPOE, using clinical rules [17]. We have already demonstrated that both the CPOE with 
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basic CDSS and clinical rules are useful early strategies for preventing medication-related 
harm [18].
In this study we report the results of a retrospective and prospective study in which the 
new ADEAS (a CDSS that uses a set of clinical rules) was compared with our conventional 
medication surveillance system (a basic CDSS within the CPOE) in order to assess its 
additional value in detecting patients with a potential ADE.
Methods
Setting
The two studies were performed in Leiden University Medical Center, a university hospital 
in Leiden, The Netherlands. Our hospital information system, Mirador® (iSOFT Nederland 
BV, Leiden, The Netherlands), includes integrated patient-specific data with demographics, 
laboratory results, discharge letters, medical diagnosis code, surgery reports, radiology 
reports and pharmacy orders. The existing CPOE system, Medicatie/EVS® (Medicator®; 
iSOFT Nederland BV), is incorporated within the hospital information system and is 
described in detail elsewhere [13]. Briefly, it provides online drug–drug interaction checks 
and drug-overdosing checks, but is not integrated with a sophisticated CDSS. The drug 
information on which the safety alerts are based is retrieved from a national drug information 
database, the ‘G-standard’ (Z-Index BV, The Hague, The Netherlands). The G-standard 
contains information about drugs available in The Netherlands, and the majority of Dutch 
pharmacy information systems use this database to support medication surveillance, 
prescribing, dispensing and logistics. Not all the features available in the G-standard are used 
within our CPOE with basic CDSS; only drug–drug interaction alerts and drug-overdosing 
alerts are generated.
Conventional medication surveillance method
The current procedure of our conventional medication surveillance is that hospital 
pharmacists perform daily retrospective checks of the drug–drug interaction and drug-
overdosing alerts overridden by the physician. As described in the previous section, these 
are standard safety alerts from the national Dutch database (the G-standard) and are not 
fine-tuned to the local situation. In practice, most of the safety alerts are ignored by the 










are collected in a Microsoft Access® database and the hospital pharmacist reviews these 
alerts the following day (except for the weekend, when the alerts are seen on Monday). If 
necessary, the hospital pharmacist checks laboratory values or co-medication, and selects 
potentially clinically relevant alerts to discuss with the prescribing physician.
New method: Adverse Drug Event Alerting System (ADEAS)
The new computerized alert system ADEAS uses clinical rules that describe potentially 
harmful drug-related situations based upon data from the hospital information system. The 
development of this expert system and the first set of clinical rules is described in detail 
elsewhere [17]. Briefly, ADEAS was composed in Gaston (Medecs BV, Eindhoven, The 
Netherlands), a guideline-based decision support framework consisting of both a guideline 
development module and a decision-support module. Selection of the potential patients at 
risk of an ADE occurs by combining data from the electronic patient file (EPF) [laboratory 
data, patient characteristics], the CPOE (prescribed medication) and the G-standard (drug 
data and drug–drug interaction data), using predefined algorithms, the so-called clinical 
rules. The guideline development module in Gaston is used to create and support the clinical 
rules. The decision support module is used to link Gaston with our hospital information 
system for the required information and to execute the clinical rules. The clinical rules 
were formulated in a multidisciplinary team using seven drug-related risk categories [17].
ADEAS processes the day’s data throughout each night, determining potential patients at 
risk, and generates its output in the Pharmacy Department every morning. During both 
studies, approximately 121 clinical rules were used by the system [17].
Study design
Retrospective study
The retrospective study was performed during a 1-month period (15 November – 15 
December 2006), in which ADEAS was compared with the conventional medication 
surveillance. For this study, all patients admitted to the hospital during this period, except 
intensive care unit (ICU) patients (because ICU uses a different EPF and CPOE), were 
included. During the study period the conventional medication surveillance method was 
performed daily as usual, as described above. ADEAS was also activated during the study 
period and the generated alerts were collected retrospectively at the end of the study. 
Consequently, no actions were taken following the alerts generated by ADEAS.
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Prospective study
The prospective comparison between the two systems was performed during a 6-month 
period (May – October 2007). For this study, all patients admitted to one general internal 
medicine ward were included. Again, during the study period the conventional medication 
surveillance method was performed daily as usual, as described above. ADEAS was also 
activated during the study period, and everyday a hospital pharmacist evaluated the list of 
alerts generated by ADEAS to determine if the alert selected a potential clinically relevant 
situation that needed discussion with the prescribing physician (except for the weekend when 
the alerts were seen on Monday). Following alerts from both ADEAS and the conventional 
medications surveillance, the hospital pharmacist visited the ward or participated in the ward 




The endpoints were the total number of alerts and the content of the alerts generated by 
the two systems.
Each day the total number of alerts, the number of patients with alerts and number of 
interventions by the hospital pharmacist were collected, as generated by the conventional 
medication surveillance method. At the end of the study period the daily total number of 
alerts and number of patients with alerts were collected, as generated by ADEAS.
The total number of alerts included duplicate alerts. Duplicate alerts can occur in the 
conventional medication surveillance; for example, when a physician prescribed then 
stopped and subsequently prescribed the same medication order again in a different dosage 
or different route, the accompanying alert is shown with each prescription. Duplicate alerts 
can also occur in ADEAS; for example, some clinical rules are built in a way that when the 
potential ADE situation continues to exist, an alert is generated every day.
Furthermore, we compared the content of the alerts (the detected potentially harmful 
situation regarding the patient) generated by the two systems. For ADEAS we selected the 
top five most frequently triggered clinical rules and determined if they were triggered by 











The endpoints were the total number of alerts, the number of unique alerts, the content 
of the alerts generated by the two systems, the number of interventions by the hospital 
pharmacist and the number of accepted interventions.
Each day, the total number of alerts, the number of unique alerts, number of patients with 
alerts and number of interventions by the hospital pharmacist were collected, as generated 
by the two systems. Follow-up was checked for each intervention to measure the number 
of interventions accepted by the physician.
We determined if an alert in ADEAS was a true positive alert, i.e. a real potential ADE. Alerts 
in ADEAS can be false positive alerts because, for example, the rule is not specific enough 
(using classes of drugs instead of individual drugs). Another scenario is that drugs are pre-
scribed by the physician as a free-text field order and not selected from the database within 
the CPOE. ADEAS cannot read free-text field items and can, in this way, miss prescribed 
drugs. Alternatively, a patient’s disease, e.g. epilepsy, is identified via their specific medication 
for that disease, in this case antiepileptic drugs; however, in some cases the patients use the 
drugs for a different indication, e.g. neuropathic pain.
By reviewing the EPF of the patients, the hospital pharmacist determined if the alert was 
true positive or false positive. The percentage of interventions was calculated compared 
with the number of true positive alerts. The overall positive predictive value (PPV) for 
ADEAS was calculated by the quotient of the number of true positive alerts and the number 
of unique alerts.
Within ADEAS, for each separate clinical rule with a true positive alert we calculated the PPV 
for potential ADE and for intervention. The PPV per rule for potential ADE was calculated 
by the quotient of the number of patients with an alert considered an actual ADE and the 
total number of patients with an alert for that rule. The PPV per rule for intervention was 
calculated by the quotient of the number of interventions and the total number of patients 
with a true positive alert for that rule.
Results
Retrospective study
During the 31 days of the study period the mean number of patients present in the hospital 
was 352 per day (exclusive of ICU patients) [SD 49.1]. The conventional medication 
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monitoring system generated a total number of 2322 signals; on average 74.9 signals per 
day (SD 34.8). Results are presented in Table 4.1. Of the 2322 signals, 350 alerts resulted 
in an action by the pharmacist. Laboratory values of the patient were checked 255 times 
(mean 8.2 per day [SD 5.3]), but further intervention was not considered necessary, and 95 
times (mean 3.1 per day [SD 3.6]) the pharmacist consulted the physician or nurse to pro- 
pose an intervention. All the alerts generated by the conventional method were drug–drug 
interaction alerts and drug-overdosing alerts.
ADEAS generated a total of 2010 signals in the same period and in the same patient 
population; on average 64.8 signals per day (SD 22.3) [Table 4.1]. Of the 121 active rules, 53 
different clinical rules were triggered at least once. The top five rules that were triggered most 
frequently are shown in Table 4.2. Of all these patients with potential harmful situations only 
some patients triggered by rule number 2 were also detected by the conventional method 
while the rest were not. The conventional system generated an alert in, for example, patients 
with the combination of an NSAID and an SSRI or corticosteroid. However, it generated 
this alert in all patients regardless of their age or concurrent medication, such as the use of 
pantoprazole. The alerts generated by ADEAS were related to laboratory value abnormalities, 
such as a declined renal function and concurrent use of drugs eliminated by the kidney, the 
absence of essential medication protecting the patient for an adverse drug reaction and other 
potentially harmful situations, e.g. a patient with a gastrointestinal tube. The data collection 
of the results with ADEAS was done retrospectively, therefore no interventions were made.
Prospective study
During the 6-month study period, measurements were performed on 139 consecutive days. 
The mean number of patients present at the general internal medicine ward was 5.6 per day 
(SD 3.1). Results are presented in Table 4.3.
Table 4.1 Results of the retrospective comparison of the Adverse Drug Event Alerting System 
(ADEAS) and conventional medication surveillance (CMS), hospital wide, during a 1-month period 
Parameter CMS ADEAS
Total numbers of alerts 2322 2010
Average number of alerts per day (SD) 74.9 (34.8) 64.8 (22.3)
Average number of patients with an alert per day (SD) 41.4 (16.7) 54.6 (13.7)
Number of interventions 95 NA










The total number of alerts with the conventional method was 177 and the number of unique 
alerts was 136. All 136 were true positive alerts. In five situations (3.7%) the pharmacist 
consulted the physician to propose an intervention, twice regarding a drug–drug interaction 
(lithium + diuretic and methadone + erythromycin) and three times concerning the dosages 
of a drug (possible incorrect dose of nitrofurantoin, cefuroxime and nadroparin regardless 
of renal function). Three times the proposed intervention was accepted by the physician.
Table 4.2 Retrospective study result of the Adverse Drug Event Alerting System (ADEAS); ‘top five’ 
most frequently triggered clinical rules during a 1-month study period
Clinical rule Total no. alerts Total no. patients
1 Opioid receptor agonist prescribed more than 2 days 
ago, and no laxative added to the therapy to alleviate 
constipation
250 220
2 Patient > 70 years of age prescribed a NSAID (not COX-2 
selective) and has no ulcer protection, or patient > 60 years 
of age prescribed NSAID (not COX-2 selective) with an 
additional risk factor for ulcer and has no PPI.
244 53
3 Patient with oral iron medication and addition prescription 
of a laxative for possible treatment of the adverse event 
constipation
198 26
4 Patient with a prescription for an oral drug given via the 
gastrointestinal tube
170 19
5 Patient with a creatinine clearance of less than 50 mL/min or 
a serum creatinine value > 150 µmol/L
137 56
COX, cyclooxygenase; PPI, proton pump inhibitor.
Table 4.3 Results of the prospective comparison of the Adverse Drug Event Alerting System (ADEAS) 
and conventional medication surveillance (CMS) on one general internal medicine ward during a 
6-month period
Alerts and interventions CMS ADEAS
Total number of alerts 177 248
Number of unique alerts 136 85
Number of true positive alerts 136 72
Total number of patients with alert 57 48
Average number of alerts per day (SD) 1.3 (1.8) 1.8 (2.2)
Average number of patients with an alert per day (SD) 0.8 (0.9) 1.0 (1.1)
Number of interventions (%) 5 (3.7) 14 (19.4)
Number of interventions accepted by physician (%) 3 (60) 10 (71)
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In the same period and in the same patient population, the total number of alerts generated 
by ADEAS was 248. The number of unique alerts was 85, of which 72 were considered 
true positive alerts, i.e. alerts regarding a real potential ADE. In 14 situations (19.4%) the 
pharmacist consulted the physician and gave additional advice. Ten times the intervention 
was accepted by the physician. The overall PPV for ADEAS was 0.85 (72/85).
Twenty different clinical rules were responsible for the 72 true positive alerts (Table 4.4). 
‘Creatinine clearance < 50 mL/min or plasma creatinine > 150 mmol/L’ was the rule with 
the highest number of alerts (12 patients). For the 20 different clinical rules, the PPV for 
actual potential ADE varied between 0.25 and 1.00 (Table 4.4). The PPV for intervention 
varied between 0.00 and 1.00 (Table 4.4). For example, the rule regarding a declined renal 
function with the highest number of alerts never led to an intervention by the pharmacist. 
The pharmacist did screen the medication for dosage errors but none were found. Still, this 
rule detects a potential harmful situation, and was therefore considered a true positive alert 
with a high PPV for an actual potential ADE, but consequently a low PPV for intervention.
Discussion
With ADEAS, different kinds of patients at risk for an ADE were detected compared with the 
conventional medication surveillance. The number of alerts with ADEAS was lower than with 
the conventional surveillance method (both total number of alerts in the retrospective study 
and unique number of alerts in the prospective study), but the percentage of interventions 
by the hospital pharmacist with ADEAS was higher.
Safety alerts generated by the conventional medication surveillance in our CPOE consist 
of drug–drug interaction signals and drug-overdosing signals. As mentioned, these safety 
alerts are retrieved from the G-standard, a national database. They are not fine-tuned to 
the local situation or specialized to individual patients or medical specialties. ADEAS was 
developed to overcome these limitations so we could detect more, and in a more sensitive way, 
patients at risk of an ADE. The strength of ADEAS is that it uses more sources of information 
from the integrated databases available in the EPF, such as laboratory data, patient age and 
concurrent medication, to search for potentially harmful situations. Consequently, the alerts 
generated by ADEAS were related to laboratory value abnormalities, such as declined renal 
function, the absence of essential medication to protect the patient for an ADE, and the 
use of a gastrointestinal tube. In this way, ADEAS has, in our hospital, an additional value 











Our study shows that, in particular, clinical rules related to unadjusted drug dosages in 
patients with declined renal function are important triggers for potential ADEs, which is in 
line with the findings of other investigators [19-23]. The additional value of the new ADEAS 
system is also illustrated by the rule ‘opioid receptor agonist and no prescription for laxative’. 
This rule gave a high number of alerts, both in the retrospective and prospective studies, 
whereas it did not generate alerts when using the conventional medication surveillance 
method.
Moreover, the added value of the new ADEAS system is also illustrated by a clinical rule 
regarding the prescription of an NSAID in a patient with a risk factor for ulcer-related bleeding 
and without a prescription for a proton pump inhibitor. The conventional system does 
generate an alert in, for example, a patient with the combination of an NSAID and an SSRI or 
corticosteroid. However, it gives an alert in all patients regardless of their age or concurrent 
medication, such as the use of pantoprazole. In the latter situation, the conventional system 
generates a false positive alert, which may lead to alert fatigue by the physician [15,24]. The 
system cannot ‘read’ the age of the patient or the concurrent medication, like ADEAS can. 
ADEAS only generates an alert when a proton pump inhibitor was absent and the patient 
was older than 70 years of age or older than 60 years of age with an additional risk factor.
Beside the content of the alerts, the number of alerts was also an endpoint in both studies. 
The total number of alerts included duplicate alerts. In an ideal system, duplicate signals are 
switched off or hidden when seen by the physician or pharmacist. Unfortunately, both our 
conventional system and the new ADEAS still show duplicate alerts. That is why we choose to 
compare the total number of alerts in the retrospective study. Although it gives less information, 
it is a reflection of our current practice. A limitation of ADEAS was that it generated more 
duplicate alerts than the conventional method. ADEAS has to become smarter in the future. 
In the prospective study we also focused on the number of unique alerts, which give more 
information about the capability of the system. Comparing the number of alerts between the 
prospective and retrospective studies is not desirable because the two studies are conducted 
on a different patient population. An official comparison of the two systems by means of PPV 
is not possible because the conventional system is a system designed to detect drug–drug 
interactions and drug-overdosing. It is not designed to be an ADE prediction system, as the 
new ADEAS is. This means we cannot calculate a PPV for the conventional method.
A limitation of the prospective study is that it was conducted on a small internal medicine 
ward. This also has consequences for the number of interventions and the proportion of 
accepted pharmacist interventions by the physician. They were higher with ADEAS than 
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with the conventional medication surveillance, but the absolute numbers were small (14 
interventions, of which 10 were accepted, vs. 5 interventions, of which 3 were accepted).
Another limitation of our study is that we compared only two particular systems, and the 
systems are only used by a few hospitals in The Netherlands. This makes the generalizability 
of our results poor; however, as with most CPOE and CDSS, different commercial and 
locally designed applications are used worldwide. Comparability and generalizability of 
these investigations is usually poor, but the methods used in the different studies can be of 
help for other investigators.
Only a relatively small number of the clinical rules active in the system ADEAS resulted in 
alerts and the PPV for some rules was low. For example, the rule regarding a declined renal 
function with the highest number of alerts never led to an intervention by the pharmacist. 
The pharmacist did screen the medication for dosages errors but none were found. More 
specific rules, with a combination of a specific drug prescription and a declined renal 
function, had higher PPVs for intervention. Our set of clinical rules needs adaptation and 
modification in order to enlarge the amount of positive alerts. Adapting the content of the 
rules during use is an acceptable way to enlarge the PPV for the clinical rules [7]. In this 
way, with smarter clinical rules, the added value of ADEAS in detecting patients at risk can 
be greater. The overall PPV for ADEAS was good (0.85), but can be better. In the future we 
should investigate the possibility of combining the features of ADEAS with the G-standard 
and the conventional surveillance method to create a more sophisticated alerting system. 
Overall, ADEAS can be seen as a first step towards more advanced clinical decision support. 
The importance of preventing ADEs by using these types of alerts and computerized systems, 
such as ADEAS, is also stressed by others [6,25-28].
We believe that interaction between pharmacists and physicians will be increasingly 
appreciated when pharmacist interventions focus on specific patients at risk of developing 
ADEs. Studies have shown that participation of clinical pharmacists with the healthcare team 
on patient rounds indeed results in improved care [29]. ADEAS may be useful to create a 
more individualized patient-oriented pharmacy service on the hospital ward. By selecting 
at risk patients, and making goal-oriented visits to the ward, the pharmacist can be more 











Compared with our conventional medication surveillance, the computerized alert system 
ADEAS selected different patients at risk of an ADE. This makes ADEAS in our hospital 
of added value to the hospital pharmacist as a suitable tool in reducing the number of 
preventable ADEs.
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Abstract
Background: With the introduction of Computerised Physician Order Entry (CPOE) in 
routine hospital care, a great deal of effort has been but into refining Clinical Decision 
Support Systems (CDSS) to identify patients at risk of preventable medication-related harm.
Objectives: This study compared a CPOE with basic CDSS and 16 clinical rules with a 
manual pharmacist medication review to detect overdose and drug–drug interactions that 
actually required a change in medication.
Methods: The study involved the review of 313 patients admitted over five months at an 
internal medicine ward where a change in medication as a result of dosing of therapeutic 
errors was detected by a manual medication review by a trained pharmacist. Subsequently, 
all these patients’ medication orders (MOs) were entered into the authors’ CPOE with basic 
CDSS. Medication orders with a safety alert indicating overdose and drug–drug interactions 
generated by the authors’ CPOE with basic CDSS were compared with the same type of 
medication errors identified through manual review. The positive predictive value (PPV), 
sensitivity and specificity compared with manual review were determined. Second, a set of 
16 clinical rules was applied to the patient and prescribing data. The overlap between the 
clinical rules and manual review was determined by comparing patients triggered by the 
clinical rule with patients with a corresponding error in the manual medication review.
Results: Manual medication review identified 57 medication errors involving overdose 
and 143 therapeutic errors of which 46 were drug–drug interactions. The CPOE with basic 
CDSS generated 297 safety alerts involving overdose (PPV 0.06, sensitivity 0.32, specificity 
0.92) and 365 safety alerts involving drug–drug interactions (PPV 0.12, sensitivity 0.96, 
specificity 0.91). The clinical rules generated 313 safety alerts identifying 39% of all the 
overdoses and therapeutic errors found in the manual review at which they were targeted. 
In 23% of the alerts generated by a clinical rule, the patients actually required a change of 
medication as indicated by the manual review. When CPOE with basic CDSS and the rules 
were combined, 66% of the overdoses and therapeutic errors were identified.
Conclusions: The authors’ CPOE with basic CDSS and the clinical rules are useful early 
strategies for preventing medication-related harm. They could be a first step towards more 
advanced decision support. These computerised systems will be even more useful in daily 









A substantial proportion of hospitalised patients experience medication-related harm 
that is preventable, for example due to incorrect dosing, contra-indicated drug choice 
or drug–drug interactions (DDIs) [1-4]. Strategies to prevent such problems are being 
developed. One such strategy is the structured review of patient medication (medication 
review) by physicians or pharmacists to identify patients with medication errors (MEs) 
that may lead to harm. In some settings, for example where clinical pharmacists do not 
routinely participate in ward rounds, this approach may have a retrospective character which 
implies late intervention, which may be too late to be effective. Moreover, this system is 
very labour-intensive, since all medication for all patients has to be systematically reviewed. 
The advantage is that the complete clinical status of each patient is taken into account 
when identifying problems. A less labour-intensive strategy is the use of computerised 
trigger systems. These systems can identify patients at risk of medication-related harm 
(adverse drug events, ADEs) using either data on the prescribed medication alone or 
the combination of medication with certain patient characteristics or clinical laboratory 
values [5-9]. An example of such a system is the Clinical Decision Support system (CDSS) 
within Computerised Physician Order Entry (CPOE) systems [10]. In The Netherlands, 
the CDSS integrated into most types of CPOE system is basic; only drug overdose and DDI 
alerts are generated. For successful identification of high-risk patients, more is required, 
such as identification of patients at risk of dosing problems in cases of clinical deviation 
from chemistry parameters or determined blood drug concentrations, or cases where a 
specific medicine for a specific disease needs to change [11,12]. Currently, some hospitals 
in The Netherlands are developing more advanced support in addition to their basic 
CDSS by creating defined clinical rules basically computerised algorithms that look for 
specific medication orders, patient characteristics and/or laboratory values that identify 
patients at risk of suboptimal therapy and of medication harm [13]. The advantage of such 
computerised system is that they limit labour input dramatically. Such systems should be 
sensitive enough to identify patients at risk, but also specific enough to generate clinically 
relevant alerts and thus prevent alert fatigue.
This study compared a CPOE with basic CDSS and 16 advanced clinical rules with a 
manual pharmacist medication review to detect overdose and DDIs that required a change 
in medication.
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Methods
Setting and study population
This study was performed in two general internal medicine wards and one gastroenterology/
rheumatology ward at the UMCG. All patients admitted for more than 24 h to these wards 
were included (313 patients). A waiver from the Medical Ethical Committee was obtained 
for this study, as the study fell within the boundaries of normal hospital routine for quality 
improvement. During the study period the system of medication ordering was a conventional 
paper-based system.
Study design and data collection
A trained research pharmacist (JEvD) visited the ward daily to collect the following data: 
patient characteristics, medical history, diseases, medication orders (MOs), and laboratory 
values. Data were extracted from the hospital information system, medical charts and 
administration charts.
Methods for identifying medication errors or patients at risk
Medication review method to identify medication errors
All MOs were reviewed by a trained research pharmacist (JEvD) with regard to the presence 
of medication errors (MEs) according to the classification scheme of The Netherlands 
Association of Hospital Pharmacists [14] and considering the complete clinical situation 
of the patient.
In this study, we included only dosing and therapeutic errors. These errors, if not corrected, 
have a high probability of leading to medication-related harm [2,15-18] and are therefore 
the prime target for CDSS.
CPOE with basic CDSS
All MOs were manually entered into a test environment in our CPOE with basic CDSS, 
the commercially available Medicator (iSOFT, Leiden, The Netherlands). The Medicator 
CDS(S) system is basic: safety alerts are generated only for overdoses or DDIs [19]. These 
safety alerts are shown to physicians during the prescribing phase when used in functioning 
systems. This medication surveillance is based on a national drug database for community 
pharmacies (the ‘G-standard,’ Z-index BV, The Hague, The Netherlands). After entering MOs 
Com
parison of m




into the system, all safety alerts generated were collected, and both MOs and safety alerts 
(overdose or DDI) were recorded in an SPSS data- base (version 14; SPSS, Chicago, Illinois).
Computer based clinical rules
Leiden University Medical Center (LUMC) has developed a computerised alert system that 
uses clinical rules to detect patients with a potential ADE or who are at risk of an ADE. The 
system uses data combined from the CPOE, the hospital information system (e.g., laboratory 
values) and the national drug information database (‘G-Standard’) to detect potential 
patients at risk. Detection is based on defined algorithms, so-called clinical rules. Currently, 
more than 100 clinical rules have been defined and agreed on by a multidisciplinary team 
including a pharmacist, a hospital pharmacist, an internal medicine specialist and a clinical 
pharmacologist. The clinical rules and the computer system have been tested and validated 
[20]. A 5-month pilot study at a general internal medicine ward was performed in the LUMC 
to compare this new computerised alert system with conventional medication surveillance 
in their CPOE/CDSS to assess its additional value. Twenty different clinical rules led to an 
alert in the small patient population admitted to this ward [21].
In the current study, which compared this computerised approach with the patients identified 
as having medication errors, we excluded four rules that were not defined as medication 
errors in the medication review, resulting in a set of 16 rules (see Table 5.5). A query was 
designed in MS Access 2003 (Microsoft, Seattle, Washington) for each clinical rule. These 
queries were applied to the patient data to assess how many patients were triggered by the 
clinical rules.
Analysis
SPSS version 14 was used for the analysis. Safety alerts generated by CPOE with basic CDSS 
were compared with overdose or DDI errors detected by the medication review method 
for all the MOs. The overlap between CDSS and medication review method was analysed 
by calculating sensitivity, specificity and positive predictive value (PPV) of the support on 
overdoses and the support on DDIs. The overlap between clinical rules and medication 
review method was analysed for those patients identified by the clinical rules as being at 
risk, and limited to patients with an identical medication error. Sensitivity and specificity 
were not calculated, since patients without an alert and with a related medication error were 
not included. The overlap was manually reviewed and subsequently analysed by calculating 
the percentage of patients who were identified as being at risk by both systems. Those 
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patients with an error that corresponded to the related clinical rule were identified only by 
the medication review method.
Results
The 313 patients making up our study population covered a wide age range of adult patients 
with diverse clinical conditions, as expected on a general medicine ward. They ranged from 
young adults with Crohn’s disease to the frail elderly with polypharmacy (Table 5.1). Using 
the medication review method, 622 dosing errors and 143 therapeutic errors were found. 
The different types of dosing and therapeutic errors are shown in Table 5.2. The ‘overdose’ 
and ‘DDI’ subtypes were detected 57 and 46 times respectively.
Table 5.1 Study population
Parameter
Age (mean ± SD)
Female (%)
Medication orders per hospital stay (mean ± SD)









Table 5.2 Frequency of different types of errors: medication review method







































In total, 297 overdose safety alerts were generated by our CPOE with basic CDSS. The PPV 
of this type of support was low (0.06), that is few of the generated safety alerts were indeed 
indicated as actual overdoses by the medication review method. The sensitivity of the support 
was higher but still not optimal (0.32) (Table 5.3).
In total, 365 safety alerts on DDI safety alerts were generated by the CPOE with basic CDSS. 
Although the PPV was low (0.12), the sensitivity of the support was high (0.96; Table 5.4). 
Almost all DDIs resulted in an alert by the system, but the majority of the problems were 
not considered as medication errors by the medication review method when other patient 
data were taken into account.
The set of 16 clinical rules generated a total of 313 alerts, 72 (23%) of which also had one or 
more related ME identified by the medication review method. These were 78 MEs in total 
(data not shown). Accordingly, 23% of the alerts identifying patients at risk of medication-
related harm actually required follow-up change in medication or some other action to 
Table 5.3 Computerised physician order entry with basic clinical decision support systems: support 
on overdose
Overdose by medication review (reference)
Medication orders (n)Yes No








Total 57 3503 3560
Sensitivity = 0.32 
Specificity = 0.92
Positive predictive value = 0.06
Table 5.4 Computerised physician order entry with basic clinical decision support systems: support 
on drug–drug interactions
Drug–drug interactions in medication 
review (reference)
Medication orders (n)Yes No










Total 46 3514 3560
Sensitivity = 0.96
Specificity = 0.91
Positive predictive value = 0.12
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prevent an ME. The percentage of patients actually requiring a change in medication for 
two rules could not be determined because no patients were appropriately triggered, and 
this percentage was zero for seven clinical rules. For the other clinical rules, this percentage 
varied between 10 and 58% (Table 5.5). The percentage was highest for the rule ‘use of an 
opioid and no prescription for a laxative’ (58%). The main focus of the rest of the clinical 
rules set was to prevent potential therapeutic errors and potential overdoses with relation 
to reduced renal function. The medication review method found 143 therapeutic errors and 
Table 5.5 Selected set of 16 clinical rules
Clinical rule No of safety alerts: that 
is patients triggered by 
clinical rule
No of patients with a 
corresponding error in 
medication review (%)
1. Clearance < 50 ml/min or serum creatinine  
> 150 mmol/l
129 23 (18)
2. Serum creatinine increase of > 50 mmol/l or 
of > 50%
37 11 (30)
3. Use of cefuroxime and clearance < 50 ml/min 7 0 (0)
4. Use of ceftazidime and clearance of < 100 ml/
min
2 0 (0)
5. Use of ciprofloxacin  and clearance of < 25 ml/
min
11 2 (18)
6. Use of ranitidine and clearance of < 50 ml/min 5 1 (20)
7. Use of cetirizine and clearance of < 10 ml/min 0 0 (e)
8. Use of sulfonamides urea derivate and 
clearance of < 10 ml/min
0 0 (e)
9. Gabapentine of pregabaline and clearance of 
< 50 ml/min
1 0 (0)
10. Use of digoxin > 0.0625 mg once daily and 
age > 70 years or clearance < 50 ml/min or low 
level of K or unknown level of K
14 0 (0)
11. A serum level of an aminoglycoside  or 
vancomycin
3 0 (0)
12. Use of opioid and no prescription  for laxative 45 26 (58)
13. Use of ciprofloxacin or norfloxacin and use of 
antiepileptic
2 0 (0)
14. Use of bisphosphonate and a drug which  has 
an effect on absorption
29 3 (10)
15. Use of iron and a drug which  forms a complex 
with iron
11 6 (55)
16. Use of azathioprine (check dose) 17 0 (0)
Total 313 72 (23)
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57 overdoses (Table 5.2). The set of 16 clinical rules thus identified 78 MEs that is 39% of 
the 143 therapeutic errors and 57 overdoses identified by the medication review. Together, 
our CPOE with basic CDSS and the clinical rules detected 18 overdoses + 44 DDIs + 69 
clinical rule alerts (excluding rule 14, which triggered patients who had already been detected 
by basic CDSS) = 131 (66%) of the 200 overdose and prescribing errors found using the 
medication review method.
Table 5.6 provides some examples of why patients found to be at risk of medication harm by 
the basic CDSS within the CPOE or the clinical rules were not considered to have medication 
errors to the medication review method.
Table 5.6 Signal with computerized physician order entry/clinical decision support systems (CPOE/
CDSS) or clinical rule but no medication error in medication review
Signal Reasoning
CPOE/CDSS overdose  for example:
Furosemide intravenous 40 mg once daily
Amoxicillin intravenous 1 g four times daily
Omeprazole intravenous 40 mg twice  daily
All these doses are well accepted in a clinical 
setting in a more severely ill patient population 
and deviate from the maximum recommended 
doses in a community  setting for which the 
medication control database was developed
CPOE/CDSS drug–drug interaction for example:
non-steroid anti-inflammatory  drugs and 
prednisolone
Due to the increased risk of gastrointestinal 
irritation this combination should be avoided or 
gastric protection should be provided. Where 
a proton pump inhibitor was administered 
simultaneously, this interaction was not 
considered a medication error, as the appropriate 
action had been taken.
Clinical rules for example number:
12. Use of opioid and no prescription  for laxative
10. Digoxin rule (Table 5.5)
1. to 10. impaired renal function and potential for 
drug overdose
12. Patient receives only a single dose of opiate 
(e.g., morphine intravenous start) or has 
diarrhea when the signal is generated
10. For example patient has low potassium levels 
but gets potassium suppletion
1. to 10. Dose has been adapted in line with 
recommendations of the level of renal 
impairment
Discussion
A considerable number of patients identified as at risk of medication-related harm by the 
two computerised systems, the CPOE with basic CDSS and the clinical rules, were found not 
to be so using the medication review method. Nevertheless, the sensitivity and specificity of 
the CPOE with basic CDSS in signalling DDIs were good, despite the low PPV. This study 
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also shows that with a small set of clinical rules, a fair proportion (39%) of the medication 
errors detected by medication review can be prevented, and when the two systems are 
combined, this result increases to 66%.
CPOE/CDSS
In their review of medication-related clinical decision support in CPOE systems, Kuperman 
et al. [22] showed that CDSS can be divided into two stages: basic support, which covers 
the basic principles of support such as DDI checking and basic dosing guidance; and more 
advanced support, which also covers more complex support such as dosing support for 
susceptible patients or guidance for medication-related laboratory testing. The Medicator 
CDSS can be considered as basic. Our set of clinical rules are a first step towards more 
advanced clinical decision support combining basic CDSS (e.g., DDIs) and advanced 
CDSS (e.g., providing dosing support for patients with renal insufficiency). Because both 
our CPOE with basic CDSS and the clinical rules set focus only on a part of the spectrum 
of medication-related problems, they should be developed further to cover more potential 
problems. However, it is first important to ensure that the current support is optimised.
Our findings show that this CPOE with a basic CDSS package generates far fewer relevant 
signals (PPV ≤ 0.12) reporting overdoses or DDIs which do not actually need a subsequent 
change in medication. Nevertheless, CPOE with basic CDSS missed a considerable number 
of overdoses (sensitivity = 0.32) identified through medication review. One reason for this 
low sensitivity may be the lack of dosing support for susceptible patients (patients with renal 
failure or geriatric patients), one of the features of more advanced support systems such as 
the clinical rules. The low PPV could be explained by the fact that the alerts are based on 
a database designed for community pharmacies (the ‘G-standard’) rather than for hospital 
pharmacies. This leads to a number of irrelevant alerts for the hospital setting, such as 
overdose alerts for doses, which are perfectly acceptable in hospital but not in ambulatory 
care. To increase the PPV, this database should be further adapted to the hospital setting to 
prevent alert fatigue in hospital physicians [23].
Despite the high sensitivity and specificity of the DDI alerts, many alerts were generated that 
did not need a subsequent change in medication (low PPV). The challenge is thus to strike an 
optimal balance between the number of alerts that do not need a follow-up and preserving 
sufficient sensitivity to catch serious DDIs or overdoses. The most relevant determinant for 
including an alert should be the severity of the consequences of the overdose or DDI [24]. 
These considerations have led to the development of the clinical rules discussed below.
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In this study, we tested a small set of clinical rules. Overall, the clinical rules meant an 
improvement in identifying patients at risk and needing an actual change in medication. 
Whereas only up to 12% of the alerts generated by our CPOE with basic CDSS required a 
subsequent change in medication, this was 23% of the alerts generated by the clinical rules. 
When the two were combined, two-thirds of the medication errors were identified.
Like the basic CDSS, some of the signals generated by the clinical rules did not require a 
subsequent change in medication. For example, rules 1-9 on the use of medication and 
reduced renal function (Table 5.5) could be made more efficient by incorporating a cut-off 
dose below which no action and thus no alert are required. Other trigger tools have been 
developed with the same intention [5-7,9,25-27]. Some of these studies compared their 
tools with other methods to identify medication errors and ADEs such as manual review 
or voluntary reports [6,7]. Others only verified the signals generated on the presence of 
medication errors or ADEs [5,9,25]. Although these studies are positive in their conclusions, 
they all showed that additional information usually needs to be collected about the individual 
patient before the actual need to change medication can be known.
Our study was limited by the fact that the medication review method was performed by only 
one investigator. However, a strict classification scheme was used to identify medication 
errors. This scheme precisely distinguished different between subtypes of medication 
errors and did not allow much room for differences in interpretation. The investigator was 
extensively trained in using this classification scheme. Another limitation of this study was 
that the set of clinical rules studied was small (only 16 rules). The majority of these rules 
focused on support for patients with renal failure and thus covered a narrow therapeutic 
area. Other studies have assessed more diverse rules, which provide further information 
about the effect of computerised rules in the field of different therapeutic areas [6,26,28].
Conclusions
We conclude that our CPOE with basic CDSS and the clinical rules are useful early strategies 
to prevent medication-related a harm. They could be a first step towards more advanced 
decision support. These computerised systems will be even more useful in daily practice 
when they are further fine-tuned to decrease the number of alerts that require no clinical 
action. Currently, however, computerised systems should still be combined with a manual 
review approach to guarantee medication safety.
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Abstract
Introduction: The computerized tool Adverse Drug Event Alerting System (ADEAS) is a clinical 
decision support system for the pharmacy and is developed as a method for performing more 
sophisticated medication surveillance. ADEAS applies clinical rules and can be used to select 
patients at risk of an adverse drug event (ADE).
Objective: This study investigates the extent in which ADEAS based interventions by hospital 
pharmacists prevent ADEs.
Setting: Leiden University Medical Center (LUMC) on five different internal medicine and 
cardiology wards.
Design: Frequencies of ADEs were estimated at baseline period and during a period after 
implementation of ADEAS (intervention period). ADEs were identified by chart review using 
a trigger list. Patients 65 years of age or older and using five or more different medications 
at admission were included. During the baseline period only conventional medication 
surveillance was performed. During the intervention period conventional medication 
surveillance and ADEAS were used. Hospital pharmacist made preventive interventions 
based upon alerts generated by ADEAS.
Measurement: Primary endpoint was the number of preventable ADEs compared in both 
study periods.
Results: In the baseline period, 223 patients were included during 240 admissions. In the 
intervention period 236 patients were included during 248 admissions. In the baseline 
period 42 preventable ADEs (0.18 preventable ADEs per admission) were found compared 
to 27 ADEs (0.11 preventable ADEs per admission) in the intervention period (P < 0.01, 
Chi square test).
Conclusion: Use of ADEAS and subsequent interventions by the hospital pharmacists 
showed a significant reduction of preventable ADEs in our hospital.
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Patient safety remains an important issue and consequently preventing patient harm in 
health care settings is crucial. Prescribing drugs to cure patients or to relieve symptoms 
represent the most common medical intervention but Adverse Drug Events (ADE) also 
attribute considerably to patient harm. Different methods to prevent ADEs are described 
in the literature, such as barcode scanning of drugs and patients, clinical pharmacist 
interventions on ward rounds, use of computerized physician order entry (CPOE) with or 
without clinical decision support systems (CDSS) and the use of robots for drug dispensing 
[1]. It is suggested that computerized tools, such as CDSS, are one of the important tools to 
prevent ADEs [1-3]. With this aim we have developed the computerized tool Adverse Drug 
Event Alerting System (ADEAS) for selecting patients at risk of an ADE [4]. ADEAS is a 
clinical decision support system for the pharmacy and is meant as a sophisticated medication 
surveillance system. It applies clinical rules combining information from multiple electronic 
sources. ADEAS is more sophisticated than our conventional medication surveillance 
because it selects through the use of algorithms, the so-called clinical rules, the patients at 
risk of an ADE. In this way the hospital pharmacist can pay attention to the medication of 
that patient who needs it the most and make preventive interventions. The development 
of this expert system including the first set of clinical rules is described in detail elsewhere 
[4]. Briefly, ADEAS was composed in Gaston (Medecs BV, Eindhoven, The Netherlands), 
a guideline-based decision support framework, consisting of both a guideline development 
module and a decision support module. Selection of the potential patients at risk of an ADE 
occurs by combining data from the electronic patient file (EPF) (laboratory data, patient 
characteristics), the CPOE (prescribed medication) and the ‘G-standard’ (National drug 
data and drug-drug interaction database). The guideline development module in Gaston is 
used to create and support the clinical rules. The decision support module is used to link 
Gaston with our hospital information system for the required patient related information 
and to execute the clinical rules. The clinical rules were formulated in a multidisciplinary 
team using seven drug related risk categories [4]. 
In a previous study we compared ADEAS with our conventional medication surveillance 
procedures and showed that ADEAS has an additional value specifically in selecting patients 
at risk of an ADE and lead to more interventions by the hospital pharmacist [5]. The aim 
of the current study is to investigate the extent in which ADEAS based interventions by 
the hospital pharmacist actually prevent ADEs in elderly patients with polypharmacy in 
the clinical setting.




The study was performed in Leiden University Medical Center (LUMC), a university 
hospital in Leiden, The Netherlands. The study was conducted on five wards: haematology, 
cardiology, combined lung/gastrointestinal diseases ward, and two combined internal 
medicine wards covering the specialism’s endocrinology, nephrology, infectious diseases, 
oncology, rheumatology and general internal medicine. Patients admitted to the five wards 
were included in the current study if they were 65 years of age or older and had five or more 
different medications at admission (polypharmacy). Exclusion criteria were admission less 
than 24 hours, scheduled admission for chemotherapy or Internal Cardiac Device (ICD) 
implantation. The study included 2 time spans: a 4-month baseline period, and a 3-month 
intervention period (see Figure 6.1). The length of the period was determined by the time 
it lasted until 250 consecutive patients were included in each period. During the baseline 
and intervention period the ADE measurements were performed. The hospital pharmacist 
made ADEAS-based intervention during the intervention period, and not during the baseline 
period. The period between the baseline and intervention period, the run-in period, was 
needed to get used to the ADEAS system and to update the system. During the entire study 
period all patients received standard pharmaceutical care which included conventional 
medication surveillance as described below. 
The research protocol was submitted for consideration to the Medical Ethics Committee 
of the LUMC before start of the study. This Committee judged the protocol as not needing 
medical ethical approval. All data were collected anonymously.
Figure 6.1 Outline study. 
Baseline period Implementation period 
(Run-in period)
Intervention period
Standard pharmaceutical care Standard pharmaceutical care Standard pharmaceutical care
  Testing and introduction of 
ADEAS
Routine ADEAS + interventions 
hospital pharmacist
Baseline measurement: 
ADE collection by chart review
  Intervention measurement:
ADE collection by chart review
Preventing A
D




During the entire study period standard pharmaceutical care was given to all admitted patients 
in the hospital including those participating in this study. Standard pharmaceutical care is 
the same as our conventional medication surveillance and consists of daily retrospective 
checks by the hospital pharmacist of the drug-drug interaction and drug-overdosing alerts 
overridden during electronic prescribing by the physician. All the ignored and overridden 
alerts are collected in a Microsoft Access® database in the central pharmacy and the hospital 
pharmacists review these alerts the following day (except for the weekend, when the alerts 
are seen on Monday). If necessary, the hospital pharmacist checks laboratory values or co-
medication, and selects potentially clinically relevant alerts to discuss with the prescribing 
physician. In addition, advices are given following therapeutic drug monitoring results. 
Our hospital information system, Mirador® (iSOFT Nederland BV, Leiden, The Netherlands), 
includes integrated patient-specific data with demographics, laboratory results, discharge 
letters, medical diagnosis code, surgery reports, radiology reports and pharmacy orders. 
The CPOE system, Medicatie/EVS® (Medicator®) (iSOFT Nederland BV, Leiden, The 
Netherlands), is incorporated in Mirador and is described in detail elsewhere [6]. Briefly, 
Medicator provides online drug-drug interaction checks and drug-overdosing checks, but 
is not integrated with a sophisticated CDSS. The drug information on which the safety 
alerts are based is retrieved from a national drug information database the ‘G-standard’ 
(Z-Index BV, The Hague, The Netherlands). The ‘G-standard’ contains information about 
drugs available in The Netherlands and the majority of Dutch pharmacy information 
systems use this database to support medication surveillance, prescribing, dispensing, and 
pharmacy logistics.
Study design
The study is a prospective, non-randomized intervention study. During baseline and 
intervention period chart review was used to collect the number of ADEs during admission. 
An independent research pharmacist (YH for baseline period and MBJ for intervention 
period) manually reviewed the paper and electronic chart of all included patients using 
a paper trigger list. This list consists of clinical symptoms and laboratory abnormalities 
which may be an indicator of the presence of a drug-related ADE. This list was composed 
using information from the Dutch POEMS study, Dutch HARM investigation, the national 
drug information database the ‘G-standard’ and other literature references [7-9]. With this 
list ADEs were searched in the chart and if possible linked to the drug use by the patient. 
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For both baseline and intervention period all charts were evaluated independently by a second 
reviewer, an internal medicine specialist (HA) and all ADEs found by the research pharmacist 
were discussed. All ADEs were classified by the two reviewers (research pharmacist and 
internal medicine specialist) to the following criteria: causality, severity and preventability. 
Causality assessment was done using a simplified Yale algorithm, also used in the Dutch 
POEMS study [10]. Severity scaling was done using the Common Terminology Criteria 
for Adverse Events (CTCAE) system [11]. Preventability was independently judged by the 
clinical knowledge of the two reviewers. ADEs are considered preventable if they were due 
to an error. When there were disagreements that affected classification of an event, the two 
reviewers met and reached consensus. If consensus could not be reached, a third reviewer, 
a hospital pharmacist (MR or IT), evaluated the event.
ADEAS based interventions
ADEAS was introduced on the five study wards during a run-in period while no changes were 
made regarding performance of standard pharmaceutical care (see Figure 6.1). ADEAS was 
run every night selecting potential patients at risk based upon the clinical rules and output was 
generated in the pharmacy department every morning. In the weekends, the retrieved patients 
and alerts were collected on Monday. During run-in and intervention period 121 clinical rules 
were implemented into the system [5]. Additional case specific information was subsequently 
collected for each patient by the hospital pharmacist and used to assess the clinical relevance 
of the alert for the specific patient. Consequently, if necessary, interventions were made by the 
hospital pharmacist following alerts from ADEAS. ADEAS alerts were categorized as follows:
1. the alert needed no intervention because the alert was false positive or the 
alert was considered not clinically relevant for this specific patient (for 
example after dose check or laboratory control);
2. the hospital pharmacist consulted the physician or nurse (by phone or by 
ward visit) to discuss the alert, for clarification, which did not result in an 
advice to alter therapy or treatment;
3. the hospital pharmacist consulted the physician or nurse and they agreed 
that the patient was at risk of a possible ADE. This resulted in an advice 
aimed to prevent the possible ADE.
For the intervention period, the total number of alerts following ADEAS, the number of 
patients with an alert and the number of alerts in each category was calculated. Following 
alerts with advice the percentage of acceptance by the healthcare professional was scored.
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The primary endpoint was the number of preventable ADEs found in the baseline period 
compared to the number of preventable ADEs in the intervention period. As secondary 
endpoints the total number of ADEs (including causality and severity assessment), the 
number of alerts generated by ADEAS and number interventions by the hospital pharmacist 
were evaluated.
Statistics
Comparison of number of preventable ADEs between baseline and intervention group was 
made using chi-square test with 1 degree of freedom (df).
We expected an average of 15 preventable ADEs per 100 admissions, based upon results of 
the Dutch POEMS study [9,12]. Approximately 50% of ADEs in hospitalized patients were 
assumed to be preventable [13]. To detect a 50% reduction in ADEs (80% power at a 0.05 
significance level) a sample size of 496 admissions equally distributed over baseline and 
intervention periods was needed.
Results
In the baseline period, 223 patients were included during 240 admissions (10 patients were 
excluded because retrospectively they did not meet the inclusion criteria). Sixteen patients 
were admitted twice and one patient was admitted three times during the baseline period. 
In the intervention period, 236 patients were included during 248 admissions (2 patients 
were excluded because retrospectively they did not meet the inclusion criteria). Thirteen 
patients were admitted twice during the intervention period. The patient characteristics are 
shown in Table 6.1. All patients were 65 years of age or older and had five or more different 
drugs at admission and stayed in the hospital more than 24 hours.
Table 6.2 shows the primary endpoint, number of preventable ADEs per admission. A total 
of 88 ADEs were collected in the baseline period in 70 out of 240 admissions (mean 0.37 per 
admission), compared to 97 ADEs in the intervention period in 70 out of 248 admissions 
(mean 0.39 per admission). In the baseline period 42 preventable ADEs (0.18 preventable 
ADEs per admission) were found compared to 27 ADEs (0.11 preventable ADEs per 
admission) in the intervention period (P < 0.01, Chi square test 1 df); a significant difference. 
Examples of preventable ADEs are constipation due to codeine and other opioids, worsening 
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of Parkinson disease symptoms due to start promethazine, hypokalemia during diuretic use 
and orthostatic hypotension due to levodopa-carbidopa overdosing. 
Table 6.3 shows the number of ADEs divided per specialism. The causality, severity and 
preventability assessment of the ADEs are shown in Table 6.4.
Results interventions ADEAS
During the intervention period ADEAS generated in total 521 alerts. Most alerts (474, 
91%) needed no intervention; after dose check or lab control the alerts were considered 
not clinically relevant for the specific patient (category 1). In 47 (9%) alerts (in 33 different 
Table 6.1 Patients’ characteristics
Baseline period Intervention period
Included patient admissions 240 248
Included number of different patients 223 236
Age 73.5 (SD 6.7) 72.9 (SD 6.0)
Sex (M) 150/240 (67%) 160/248 (65%)
Medium length of stay (day) 6.2 (SD 6.4, range 1–48) 5.9 (SD 6.4, range 1–38)































* Not included during baseline due to another pilot study.
Table 6.2 Primary endpoint: number of preventable ADEs
ADEs Baseline period
(N = 240 admissions)
Intervention period
(N = 248 admissions) P-value*
Not preventable 46 (0.19/admission) 70 (0.28/admission)
Preventable (possible and definitely) 42 (0.18/admission) 27 (0.11/admission) P < 0.01
Total 88 (0.37/admission) 97 (0.39/admission)
* Chi square test with 1 df.
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Table 6.3 Number of ADEs found with chart review per specialism
Specialism’s wards Baseline period:
ADEs = 88 (0.37/admission)
Intervention period:































* Not included during baseline due to another pilot study.
Table 6.4 Causality, severity and preventability assessment of ADEs
ADE criteria Baseline period (N = 88) Intervention period (N = 97)
Causality
≥ -3 and < 0 (unlikely)













4 – life-treating or disabling





















patients) the hospital pharmacist consulted the physician (category 2 & 3). In 39 out of 47 
consults the pharmacist gave additional advice to prevent the possible ADE (category 3). 
Sixteen advices were accepted by the nurse or physician (41%) and the remaining 23 advices 
were not accepted or it was unknown if they were accepted. The flowchart of the results 
with ADEAS is shown in Figure 6.2. The different types of advice given by the hospital 
pharmacist are shown in Table 6.5.
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Figure 6.2 Results alerts with ADEAS during intervention period. 




(N = 474; 91%)
Alerts with consult 
(N = 47; 9%)
Consult with
no advice (N = 8) 
Consult with
advice (N = 39)
Advice accepted 
(N = 16)
Advice not accepted or
unknown if advice was 
accepted
(N = 23)
Table 6.5 Types of advices following alerts from ADEAS during intervention period




Monitoring side effects 2
Take drugs separately 8
Add medication 8
Therapeutic drug monitoring 2
Total 41*








This study shows that the ADEAS based interventions by the hospital pharmacist were 
effective in reducing the number of possible and definitely preventable ADEs. The number 
of preventable ADEs was significantly lower in the intervention period compared to the 
baseline period. However, the total number of ADEs before and after implementation of 
ADEAS remained constant.
The finding that the number of preventable ADEs is lower in the intervention period, is 
in line with our expectations. In the intervention period ADEAS was used, and ADEAS 
is designed to select patients with a potential ADE. Alerts generated by ADEAS lead to an 
action by the hospital pharmacist regarding the patient at risk, which could have prevented 
the ADE. Potential ADEs, in contrast to actual ADEs, are medication errors with the 
potential to cause injury but which do not necessarily cause any injury [8,14]. Medication 
errors, or extrinsic harm, are related to the manner the drugs used and can be prevented by 
interventions more easily. In particular, ADEs due to error or negligence are preventable [15]. 
Indeed, the alert system ADEAS contains clinical rules that search for these situations, such 
as medication dosages not adapted to a declined renal function, an opioid agonist prescribed 
without a laxative or a drug-drug interaction between cyclosporine and voriconazol without 
therapeutic drug monitoring.
In contrast to the number of preventable ADEs, the total number of ADEs was equal in the 
baseline and intervention period, caused by a higher number of non-preventable ADEs 
in the intervention period. Non preventable ADEs, also referred to as intrinsic harm or 
adverse drug reactions, are the result of the pharmacological properties of the drug itself [3]. 
An explanation for this can be the non-equal distribution of specialisms between baseline 
and intervention period. The inclusion of all consecutively admitted patients who met the 
inclusion criteria resulted in this non equal distribution of specialisms. In the intervention 
period more patients were admitted at the nephrology and general internal medicine 
department. The fact that more patients were admitted at the nephrology department in 
the intervention period could have had an influence on the relatively large proportion non-
preventable ADEs in the intervention period. Indeed in the intervention period 27 ADEs 
were found in patients admitted to the nephrology department compared to 8 in the baseline 
period. At the nephrology department mostly kidney transplant patient are admitted which 
use immunosuppressive medication causing frequently adverse drug reactions which are 
by definition unpreventable. For example in the intervention period 8 non-preventable 
ADEs were found regarding hyperglycaemia and deregulation of diabetes mellitus due to 
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prednisolon. The median length of stay and the study population, the elderly patient with 
polypharmacy, was equal in baseline and intervention period.
The number of ADEs per admission in the baseline period and the percentage considered 
preventable in our study is comparable with ADE rates found in the literature [13]. The 
Dutch POEMS study found 15 preventable ADEs per 100 admissions [9,12]. We found a 
comparable number of 17.5 possible or definitely preventable ADEs per 100 admissions in 
the baseline period. Due to our ADEAS based interventions this number declined to 11 
possible or definitely preventable ADEs per 100 admissions, a 37% reduction.
This study does not allow to indirectly compare ADEAS to the effects of other interventions 
aimed at reducing medication errors or ADEs. Most studies investigating the effect of CPOE 
and CDSS on medication errors and ADEs differ substantially in their setting, design, quality 
and thus, their results [16]. However, it seems that the use of CPOE and CDSS can reduce 
ADEs [2,16,17]. For example, implementation of CPOE with basic CDSS in two Dutch 
hospitals reduced the incidence of medications errors but did not demonstrate a direct effect 
on actual patient harm [9]. In addition, a computerized reminder system that used rules to 
alert physicians of using four preventive therapies (pneumococcal vaccination, influenza 
vaccination, subcutaneous heparin and aspirin at discharge) showed a significant increase 
in the rate of delivery of such therapies [18]. 
A limitation in our study is the use of chart review to search and detect ADEs. The incidence 
rates of ADEs have shown to be dependent on the method of detection used [19]. However, 
we choose chart review because it is a well-known and classical way of adverse (drug) event 
detection [15,20]. More importantly, studies comparing different methods of ADE detection 
found that chart review was more effective in detecting events manifested primarily by 
symptoms, such as change in mental status, nausea and vomiting, rigors and hypotension 
and less effective in detecting changes in laboratory values [19,21]. Clearly, most ADEs 
will be found with a combination of methods. For that reason, we used a paper trigger list 
with symptoms and laboratory abnormalities in combination with review of paper and 
electronic charts.
Another limitation of our study is that we used two different research pharmacists to perform 
chart review for the baseline and the intervention period. This may have attributed to the 
difference in number of ADE between the two periods. But both persons used the same 
trigger list, same clinical research form and same instruction and the second reviewer, the 
internal medicine specialist, was the same in both periods. We also did not estimate interrater 
scores for ADE, causality, severity and preventability assessments. Indeed, the Dutch POEMS 
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study showed that there was only fair agreement on the assessment of preventable ADEs, 
and it was suggested that the best practical solution is a combination of a pharmacist and a 
physician for scoring, like we used in our study [10]. We agree with Haynes et al. that it is 
still a challenge to assess ADEs incidence in a reliable way [22]. Despite the fact that many 
other variables such as patient characteristics and setting, may influence ADE rates, we found 
comparable numbers as reported in the literature. Therefore, we believe that inter observer 
variability may have played only a minor role in our current study.
In our study confounding bias cannot be ruled out since the performance of the study may 
have led to more awareness related to medication safety.
A relatively small number of the clinical rules active in the system ADEAS resulted in alerts, 
and the “potential ADE capture rate” of some clinical rules was not high. Only 9% of the 
alerts resulted in an action by the hospital pharmacist. The other 91% of the alerts needed 
no intervention, but frequently dose checks and lab control were performed by the hospital 
pharmacist. For example a rule regarding the combination of a drug and a declined renal 
function can result in no intervention when the dosage of the drug is already correctly 
adapted. But still it is a useful clinical rule with alert that leads to a check by the pharmacist. 
Maybe our set of clinical rules needs some adaptations and modifications in order to further 
enlarge the amount of positive alerts, for example special clinical rules for elderly patients 
or transplantation patients. Adapting the content of the rules during use is an acceptable 
way to enlarge the positive predictive value for the clinical rules [23]. With smarter clinical 
rules, the added value of ADEAS in detecting patients at risk can even be increased.
Overall we can conclude that the use of the clinical decision support system ADEAS for 
the pharmacy which combines patient data and drug information available from multiple 
sources, helps to reduce preventable ADEs and to improve patient safety.
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Abstract
Introduction: Our advanced clinical decision support (CDS) system, entitled ‘adverse 
drug event alerting system’ (ADEAS), is in daily use in our hospital pharmacy. It is used by 
hospital pharmacists to select patients at risk of possible adverse drug events (ADEs). The 
system retrieves data from several information systems, and uses clinical rules to select the 
patients at risk of ADEs. The clinical rules are all medication related and are formulated 
using seven risk categories.
Objective: This study’s objectives are to 1) evaluate the use of the CDS system ADEAS in 
daily hospital pharmacy practice, and 2) assess the rule effectiveness and positive predictive 
value (PPV) of the clinical rules incorporated in the system.
Setting: Leiden University Medical Center, The Netherlands. All patients admitted on six 
different internal medicine and cardiology wards were included.
Measures: Outcome measures were total number of alerts, number of patients with alerts 
and the outcome of these alerts: whether the hospital pharmacist gave advice to prevent a 
possible ADE or not. Both overall rule effectiveness and PPV and rule effectiveness and 
PPV per clinical rule risk category were scored. 
Study design: During a 5-month study period safety alerts were generated daily by means 
of ADEAS. All alerts were evaluated by a hospital pharmacist and if necessary, healthcare 
professionals were subsequently contacted and advice was given in order to prevent possible 
ADEs.
Results: During the study period ADEAS generated 2650 safety alerts in 931 patients. In 
270 alerts (10%) the hospital pharmacist contacted the physician or nurse and in 204 (76%) 
cases this led to an advice to prevent a possible ADE. The remaining 2380 alerts (90%) were 
scored as non-relevant. Most alerts were generated with clinical rules linking pharmacy and 
laboratory data (1685 alerts). The overall rule effectiveness was 0.10 and the overall PPV 
was 0.08. Combination of rule effectiveness and PPV was highest for clinical rules based 
upon the risk category ‘basic computerized physician order entry (CPOE) medication safety 
alerts fine-tuned to high risk patients’ (rule efficiency = 0.17; PPV = 0.14).
Conclusion: ADEAS can effectively be used in daily hospital pharmacy practice to select 
patients at risk of potential ADEs, but to increase the benefits for routine patient care and to 
increase efficiency, both rule effectiveness and PPV for the clinical rules should be improved. 
Furthermore, clinical rules would have to be refined and restricted to those categories that 
are potentially most promising for clinical relevance, i.e. ‘clinical rules with a combination 
of pharmacy and laboratory data’ and ‘clinical rules based upon the basic CPOE medication 
safety alerts fine-tuned to high risk patients’.




Adverse drug events (ADEs) can occur at any point the medication process, from ordering 
and prescribing to dispensing, reconstitution and drug administration [1,2]. As advanced 
information technology plays an important role in the improvement of medication safety, 
we have opted to use one of the technologies available to prevent ADEs [1]. Different of such 
technologies are described in literature, for example barcode scanning to identify both drugs 
and patients, use of computerized physician order entry (CPOE) with or without clinical 
decision support (CDS) system, smart pumps and the use of robots for drug dispensing [3,4]. 
Although no randomized control trials were performed, there are investigations showing 
that a reduction in ADEs can be reached by means of using CPOE in combination with CDS 
systems [5-7]. CDS systems can range from basic to more advanced [8]. Basic CDS systems, 
for example, include basic dosing guidance or drug–drug interaction checking only. More 
advanced CDS systems can include dosing support for renal insufficiency and guidance for 
medication-related laboratory testing [8].
The information system in use in our hospital is Mirador® with incorporated CPOE system 
Medicatie/EVS® (Medicator®)(iSOFT Nederland BV, Leiden, The Netherlands), is a basic 
CDS system which provides online basic medication safety alerts [9]. The safety alerts in 
our CPOE system are retrieved from a Dutch national drug database (the G-Standard). 
This database contains safety information on all drugs registered in The Netherlands, and 
provides drug–drug interactions information, duplicate orders and overdoses alerts [10]. In 
order to reduce the limitations of a basic CDS system such as Medicator® [11-13], we have 
developed an advanced CDS system, named ‘adverse drug event alerting system’ (ADEAS). 
ADEAS is in use in the hospital pharmacy and it is used by hospital pharmacists as medication 
surveillance tool to select patients at risk of possible ADEs. The system retrieves data from 
several information systems, and uses clinical rules to select the patients at risk of ADEs. 
Selection of these patients potentially at risk occurs by combining data from the electronic 
patient databases (EPD) (laboratory data, patient characteristics), the CPOE (prescribed 
medication) and the ‘G-standard’ (National Dutch drug database).
In a previous study, we compared ADEAS with our CPOE with basic CDS system and 
showed that ADEAS has an additional value in selecting different kind of patients at risk 
of ADEs. This study showed that the basic CDS system generated safety alerts regarding 
drug–drug interactions and drug-overdosing only, whereas ADEAS also generated alerts 
regarding declined renal function and other laboratory abnormalities. It was proven that 
alerts generated by ADEAS led to a larger number of interventions by pharmacists when 
compared to alerts generated by the basic CDS system [14].
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The objectives of this current study were: (1) to evaluate the use of ADEAS in daily practice 
as a CDS system for hospital pharmacists; (2) to assess the rule effectiveness and positive 
predictive value (PPV) of the clinical rules incorporated in the ADEAS system.
Study context
Organizational setting
The study was performed in the Leiden University Medical Center (LUMC), a teaching hospital 
in Leiden, The Netherlands, forming part of Leiden University. The study was conducted on 
six clinical wards: haematology (hemat), cardiology (cardio), combined lung/gastrointestinal 
diseases ward (lung and gastro), short stay internal medicine (short stay) and two combined 
internal medicine wards, one specializing in endocrinology, nephrology and general internal 
medicine (called mixed internal 1) and one specializing in infectious diseases, oncology and 
rheumatology (called mixed internal 2). All patients admitted on these wards during the study 
period (a 5-month period, from September 2009 up to January 2010) were included in this 
study, irrespective of their age or the number of different drugs at the time of admission. All 
included patients were screened on a daily basis by ADEAS throughout their stay in hospital.
System details and full description of system in use
Description of CDS system ADEAS
ADEAS was composed by means of Gaston (Medecs BV, Eindhoven, The Netherlands), which 
is a guideline-based decision support framework, consisting of both a guideline development 
module and a decision support module [15,16]. The guideline development module consists 
of a task network module [17] which describes the structure (‘logic’ or ‘flow’) of the guideline 
by means of a set of primitives (such as observations, decisions, and actions) and which 
provides domain specific knowledge in the form of one or more terminology items. For the 
guideline development module, we defined the following terminology items: drug, laboratory 
values, drug–drug interactions and patient characteristics. The data used for ADEAS can 
be specified as follows. The data for the ‘drug’ and ‘drug–drug interactions’ sections were 
imported from the national Dutch drug information database (the ‘G-standard’). The data 
regarding laboratory values and patient characteristics were imported from the hospital 
information system, Glims® (MIPS Diagnostics Intelligence, Clinisys, UK) and Mirador®. The 
information about drug use for specific patients was imported from the CPOE, Medicator®.
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A decision support module was used to link Gaston with our hospital information system 
in order to be able to import the required information and to execute the clinical rules. 
Gaston was originally designed as a CDS system within a CPOE. We, however, preferred to 
use ADEAS as a pharmacy decision support system, not incorporated in the CPOE. This 
resulted in technical adaptations to the reporting technology.
The primitives and terminology items were combined and used to create and integrate 
the clinical rules into the system. The terminology items were moved to the desired field 
(positive or negative preferences). Per item, sub items such as dosage or administration 
route for a drug could be added. Most clinical rules consisted of simple observations of one 
or more positive and/or negative term preferences, for example a drug prescription and the 
presence of a laboratory value or a drug prescription and the absence of a laboratory value. 
More complicated clinical rules were built as a flowchart using the primitives. We started 
with a set of 121 clinical rules. Figure 7.1 offers the reader insight in ADEAS and gives the 
reader an example of how clinical rules were formed.
More detailed information about the development and validation of our system including 
the first set of clinical rules has been described elsewhere [18].
Description of clinical rules
The contents of the clinical rules were established with the help of a multidisciplinary team. 
From a drug perspective seven risk categories were defined which were used to create 
clinical rules. For each drug or drug class, the seven risk categories were discussed and this, 
subsequently, resulted in agreement and definition of a clinical rule [18]. The seven risk 
categories specified by the multidisciplinary team are:
1. Combination of biochemical laboratory values with the initiation of drug use
Examples of clinical rules: A) patient start with an aminoglycoside and the estimated 
glomerular filtration rate (eGFR) < 50 ml/min, B) patient start with lithium and eGFR 
< 50 ml/min, C) patient start with allopurinol > 200 mg and eGFR < 50 ml/min, and D) 
no international normalized ratio (INR) 3 days after start phenprocoumon.
2. Combination of biochemical laboratory values or therapeutic drug monitoring values 
with the ongoing use of a drug
Examples of clinical rules: A) patient with sotalol > 160 mg and eGFR decline below 50 
ml/min, B) INR > 6 during use of coumarin anticoagulant, and C) no therapeutic drug 
monitoring 2 days after start or dosage change of aminoglycoside or vancomycin.
3. Combination of use of a drug with non-use of a drug, the latter indicated for the 
prevention of an ADE
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Examples of clinical rules: A) patient with co-trimoxazole and no folic acid, and B) patient 
with opioid agonist of > 2 days and no laxative.
4. Medication used to treat an ADE
An example of a clinical rule: A) patient with inhibitor of angiotensin converting enzyme 
(ACE-inhibitor) and anti-cough medication.
5. Basic CPOE medication safety alerts fine-tuned to high risk patients
Examples of clinical rules: A) patient with a quinolone antibiotic and interacting co-
medication regarding absorption, B) patient with drug–drug interaction between non-
steroidal anti-inflammatory drug (NSAID) and ACE-inhibitors or angiotensin receptor 
blockers (ARBs) and eGFR < 50 ml/min, C) patient with anti-epileptic medication and 
start a quinolone antibiotic, and D) Patient with start aminoglycoside and prescription 
of cisplatin in previous 6 months.
6. Safety alerts from inspection authority
Examples of clinical rules: A) patient with azathioprine in dose > 150 mg/day, and B) 
patient with methotrexate in non-weekly dose schedule.
7. Medication errors and high risk drug situations
Examples of clinical rules: A) patient > 80 years of age and Beers-list medication, B) 
patient with aspirin low dose and co-medication with ulcer risk and no proton pump 
inhibitor, and C) patient with gastrointestinal tube.
Methods
Study design
The evaluation of ADEAS was investigated in a prospective non-randomized observational 
study. All patients admitted on one of the six wards used for this study were screened on a 
daily basis by ADEAS throughout their stay in hospital. ADEAS was used as a CDS system 
by the hospital pharmacist to select patients at risk of possible ADEs. The system ran every 
night selecting patients potentially at risk based upon the clinical rules. The output was 
generated in the pharmacy department every morning. Every day (except during weekends; 
safety alerts produced during weekends were read on Mondays) all the safety alerts were 
reviewed in detail by one of the hospital pharmacist. Additional case specific information 
was subsequently collected for each patient in the EPD to assess the clinical relevance of the 
alert for that specific patient. Consequently, if necessary, the hospital pharmacist contacted 
the physician or nurse to give advice or to intervene.
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Outcome measures
To evaluate the use of the ADEAS system for daily hospital pharmacy practice the following 
items were scored: 1) the total number of alerts generated by ADEAS, 2) the number of 
patients with an alert, and 3) the outcome of the alerts; whether the hospital pharmacist gave 
advice to prevent a possible ADE or not. Of all the advice given by the hospital pharmacist 
the type of advice was scored. In addition, the percentage of acceptance of the advice by the 
healthcare professional was scored as well.
The rule effectiveness and PPV of all the rules triggered in ADEAS, and of each rule risk 
category separately, were calculated.
Measurement
To measure the outcome of the alerts, all ADEAS alerts were divided into the following 
categories:
Alert category (1) alert considered non-relevant.
After detailed review by the hospital pharmacist of the alert (for example, after dose check 
or laboratory value check in the EPD), the alert was considered not clinically relevant for 
this specific patient.
Alert category (2) alert resulting in contact with physician or nurse.
After review of the alert, the hospital pharmacist contacted the healthcare professional (by 
phone or by means of personal advice, while visiting the ward) in order to discuss the alert 
and get further clarification about the reasons for prescribing. This contact may or may not 
lead to an advice to adjust treatment in order to prevent possible ADEs.
Alert category (3) alert with advice/intervention.
Category 3 includes all actual advice given after contacting the healthcare professional.
If advice was given by the hospital pharmacist, the following types of advice were distinguished: 
1) advice to adjust the dose; 2) advice to discontinue or suspend medication; 3) advice to 
change medication; 4) advice to continue medication but to monitor side effects; 5) advice 
to adjust the time drugs are administered; 6) advice to add extra medication; and 7) advice 
to initiate drug blood level measurement or other laboratory control such as renal function.
To measure the acceptance rate of all advice given, we checked the documented modifica-
tion in therapy. The hospital pharmacist who gave the advice checked the patient’s EPD the 
following day in order to ensure that the advice was adhered to.
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All generated alerts were specified according to one of the seven risk categories for the 
clinical rules, described above [18]. Both the overall rule effectiveness and PPV and the rule 
effectiveness and PPV per rule risk category were scored. A measure of rule effectiveness 
is the ratio of the number of alerts resulting in contact with healthcare professional to the 
total number of alerts generated by ADEAS. We used rule effectiveness as a variant of rule 
efficiency. Rule efficiency is the probability of an alert leading to action of by the pharmacist 
[19]. The PPV is the probability of an alert leading to advice/intervention. The PPV was 
calculated by the quotient of the number of advice/interventions to prevent a possible ADE 
and the total number of alerts generated by ADEAS [19].
Results
Results number of alerts and alert outcome
During the 5-month study period (September 2009 – January 2010) ADEAS generated a 
total of 2650 alerts for 931 patients. This is a mean of 17 alerts per day. The main results 
are shown in Table 7.1 and Figure 7.2. Most alerts, 2380 (90%) out of 2650, were rated as 
alerts for category 1 (alert considered non-relevant). In 270 (10%) out of these 2650 alerts, 
the hospital pharmacist contacted the physician or nurse (alert category 2). In 204 (76%) 
out of these 270 alerts, the pharmacist gave advice to prevent the possible ADE (alert 
category 3). For 204 times advice was given, 128 instances were accepted by the healthcare 
Table 7.1 Main results: number of alerts with ADEAS, alerts outcome and overall rule effectiveness 
and PPV
Total number of alerts 2650
Total number of patients with alerts 931
Number of alerts, alerts category 1 (alert considered non-relevant) 2380 (90%)
Number of alerts, alert category 2 (alerts resulting in contact with prescriber or 
nurse)
270 (10%)
Number of alerts, alert category 3 (alert with advice/intervention) 204 (7.6%)
Number of alerts for which advice was given and adhered ti 128 (4.8%)
Rule effectiveness (overall) 270/2650 = 0.10
PPV (overall) 204/2650 = 0.08
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Figure 7.2 Main results: number of alerts with ADEAS and alert outcome. 
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professionals. For the remaining 76 times advice was given, advice was either not adhered 
to or it is not clear whether advice was adhered to. In total, 128 (4.8%) out of 2650 alerts led 
to a documented modification in therapy. The alert outcome representing the spread over 
the study wards is shown in Figure 7.3.
All advice given by the hospital pharmacists is specified in Table 7.2. Sometimes there was 
more than one type of advice given following an alert, for example, to both add medication 
and monitor for side effects.
Results rule effectiveness and PPV
The overall rule effectiveness of ADEAS was 0.10 (270/2650) and the overall PPV was 0.08 
(204/2650) (Table 7.1).
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Figure 7.3 Results number of alerts with ADEAS and alert outcome divided between different wards. 
Total alerts: total number of alerts generated by ADEAS (category 1 + category 2)
Alert category 1: number of alerts considered non-relevant
Alert category 2: number of alerts resulting in contact with physician or nurse
Alert category 3: category 3 includes all actual advice given after contacting the healthcare professional
Advice accepted: number of alerts from category 3 for which advice was given by hospital pharmacists 
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Table 7.2 Type of advice given following alerts from ADEAS
Type of advice Number of alerts
Dose adjustment 67
Discontinue or suspend medication 12
Change medication 13
Monitor side effects 9
Take drugs separately/adjust administration time 45
Add medication 37
Measure drug blood lever or other laboratory control 34
Most alerts, 963 alerts, were generated by clinical rules from risk category 1 (‘Combination of 
biochemical laboratory values with the initiation of a drug’). Clinical rules from risk category 
2 (‘Combination of biochemical laboratory values or therapeutic drug monitoring values 
with the ongoing use of a drug’) generated 722 alerts. Clinical rules from risk category 5 
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Figure 7.4 Results number of alerts with ADEAS and alert outcome divided per clinical rule risk 
category. 
Total alerts: total number of alerts generated by ADEAS (category 1 + category 2)
Alert category 1: number of alerts considered non-relevant
Alert category 2: number of alerts resulting in contact with physician or nurse
Alert category 3: category 3 includes all actual advice given after contacting the healthcare professional
Advice accepted: number of alerts from category 3 for which advice was given by hospital pharmacists 































































Figure 7.5 Results rule effectiveness and PPV per clinical rule risk category. 
Rule effectiveness: the ratio of the number of alerts resulting in contact with physician or nurse tot the 
total number of alerts generated by ADEAS.
PPV (positive predictive value): the quotient of the number of advices/interventions to prevent a possible 
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(‘Basic CPOE medication safety alerts fine-tuned to high risk patients’) generated 437 alerts. 
In Figure 7.4, the alert results per clinical rule risk category are shown. The PPV was highest 
for clinical rules from risk category 5 (0.14). Rules from this category had the second highest 
rule effectiveness score (0.17). Consequently, this category had the highest combination of 
rule effectiveness and PPV. Figure 7.5 shows all the results for rule effectiveness and PPV.
An extra ordinary result is the high rule effectiveness of 0.29 for rules from category 4 
(‘Medication used to treat an ADE’) together with a PPV of zero. This rule category covered 
one clinical rule (Patient with an ACE-inhibitor and anti-cough medication) and resulted in 
7 alerts during the study period. In two instances, the pharmacist contacted the physician 
but this never led to an advice. This rule can be considered of low clinical relevance.
Discussion
Answer to study questions
In this study we evaluated the usefulness of the CDS system ADEAS for selecting patients 
at risk of ADEs in daily hospital pharmacy practice. The main result of this study is that 
the ADEAS system can be used for this goal, but that both rule effectiveness and PPV 
would have to be increased in order to use the ADEAS system effectively. The overall rule 
effectiveness score was 0.10. This means that 10% of the safety alerts generated by means of 
ADEAS resulted in direct contact by hospital pharmacist and healthcare professional. The 
overall PPV was 0.08. This means that 7.8% of the alerts resulted in advice or intervention 
to prevent possible ADEs. In addition, the majority of advice given by the pharmacist was 
accepted. ADEAS is considered most useful with rules from risk category 1, 2 and 5, because 
those rules had the highest combination of rule effectiveness and PPV (risk category 5) and 
the highest number of alerts (risk categories 1 and 2). This is explained in more detail in 
Section 5.4 of this paper.
A rule effectiveness of 0.10 implicates that a large number of alerts (90%) were scored as 
non-relevant (alert category 1). The authors feel it is important to comment that all alerts 
considered in this study could have led to potential ADEs, but that in certain cases, alerts 
were rated as non-relevant, after detailed review of the patient’s EPD. There are a few of such 
situations in which an alert was considered non-relevant: 1) one such example is an alert 
generated by the clinical rule regarding the use of a quinolone antibiotic and a declined renal 
function (eGFR < 30 ml/min). It could be that the physician in this specific case had already 
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adjusted the dose himself, taking into consideration the patient’s renal function. In that case, 
the hospital pharmacist actively checked the patient’s EPD following the alert, but found 
that the alert was non-relevant because dose adjustment had already taken place; 2) another 
example is an alert generated by the clinical rule regarding absence of INR laboratory results 
during phenprocoumon therapy. It could be that the INR laboratory control was ordered 
the day the pharmacist reviewed the alert, but that the results were not yet known by that 
time. Because it was clear to the pharmacist that laboratory control of INR had already been 
ordered, the pharmacist rated the alert as non-relevant; 3) another situation in which the 
pharmacist considered an alert as non-relevant that can easily be explained occurred on 
the cardiology ward. Most patients at this ward received an intervention procedure, such 
as implantation of an implantable cardioverter defibrillator or a percutaneous transluminal 
coronary angioplasty. These patients often have a short period of declined renal function 
and high INR values after the procedure but, however, it is known that values improve 
quickly. In those cases, alerts do not lead to intervention and medication does not need to 
be adjusted; and 4) a last reason for considering alerts as non-relevant is the fact that alerts 
reappear for the same patient – the alerts are then counted and included in the total number, 
but intervention only has to take place once.
All reasons mentioned above are related to the low sensitivity and or low specificity of the 
created clinical rules in ADEAS. In some cases the clinical rules were adapted during the 
study, to enlarge their sensitivity or specificity. To lower the number of non-relevant alerts, 
both rule effectiveness and PPV of ADEAS should be increased in the future. One possible 
adjustment is to add more sub items to a rule. For example the sub item ‘drug dosage’ can 
be added in a rule regarding drug use and declined renal function. Or the sub items ‘ward’ 
or ‘specialty’ can be added in a rule considered not relevant for specific patient categories. 
In addition, the authors recommend that a technical solution should be found to lower the 
amount of duplicate alerts. This can be achieved by including a sub item that takes into 
consideration the previous alerts generated for the same patient. In order to increase the 
effectiveness of ADEAS for routine patient care, it can be concluded that the clinical rules 
have to be refined and potentially restricted to those categories that are clinically relevant.
Strengths and weaknesses of the study
One of the main strengths of our study is that ADEAS was tested and evaluated in the 
actual clinical setting it was intended for: in routine daily practice, and not just in a research 
setting. This makes the evaluation highly clinically valuable and the results very useful and 
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significant. Actually testing ADEAS in the actual clinical setting meant that the result could 
be applied directly in clinical practice.
A limitation of our study is that we did not measure ADEs as endpoint. Had we done so, 
we could have said more about the ability of ADEAS to prevent actual ADEs. In a study 
not yet published, we investigated the effect of ADEAS on ADEs. Studying a subpopulation 
consisting of elderly patients with polypharmacy, it was proven that the use of ADEAS 
resulted in a significantly lower number of preventable ADEs. ADEAS did not have an 
effect on the total number of ADEs (unpublished data). Our current study is a prospective 
observational study to evaluate the use of ADEAS in daily practice and measurement did 
not include ADEs.
Another limitation of our study is that we only based the advice acceptance rate on documented 
modifications in therapy. The acceptance rate was measured by checking the EPD of the 
patient the next day to verify if the advice was adhered to. We did not interview the healthcare 
professional for a complete follow-up, however. We scored a total of 76 (37%) out of 204 
advices by the hospital pharmacist, for which advice by the hospital pharmacist was either not 
adhered to or for which it was unknown whether advice was adhered to. In many cases the 
acceptance rate could not be verified in the documentation because the patient had already 
been discharged the following day; this is often the case on the cardiology ward or on the 
short stay ward, where patient turnover is high. At the cardiology department only 2 out of 30 
instances of advice were scored as accepted, and at the short stay ward 4 out of 14. Moreover, 
the advice ‘monitor side effects’ (given in 9 cases) could not be verified either, because it was 
not a documented modification in therapy. This could be a possible explanation why the 
acceptance rate of 63% is rather low compared to other investigations. Two studies in which 
pharmacists gave dosages advice in case of impaired renal function showed an acceptance 
rate of 74% (141 of 191 recommendations accepted) and 88% (142 of 162 recommendations 
accepted) respectively [20,21]. In addition, the study of Silverman et al. reported an acceptance 
rate of 78.7%, 90.9% and 92.2% in their three different study periods [19].
Finally, another minor limitation of our study is that we did not consider the time element. 
With time measurement a better judgment can be made whether the found PPV and rule 
effectiveness is worthwhile for the efforts of the hospital pharmacist. We did measure time 
for a study that has not yet been published, also mentioned above, regarding a subpopulation 
consisting of elderly patients with polypharmacy. The amount of time measured required 
for ADEAS was an acceptable maximum of approximately 1 hour per day per hospital 
(unpublished data).
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Results in relation to other studies
The percentage of safety alerts resulting in advice or intervention by the hospital pharmacist 
(10%) seems low, but is comparable to or even higher than other international investigations. 
Jha et al. investigated a commercial computerized surveillance system and found that in 30 
(11.3%) out of 266 reviewed alerts the physician was contacted [22]. During a two month 
period, Kilbridge et al. evaluated 4604 triggers from a computer-based ADE surveillance 
system with rules of which 206 led to an intervention (4%) [23]. The intervention percentages 
found by Silverman et al. with their computer-based monitoring system with rules ranged from 
5% to 13% [19]. In an earlier study we compared ADEAS with our conventional medication 
surveillance using only safety alerts from the Dutch national database G-Standard (basic 
CPOE safety alerts). The percentage of interventions with ADEAS was three times as high [14].
From our study, we can conclude that the variation of rule effectiveness and PPV among 
the categories of clinical rule was highly variable. However, this is observed in the literature 
as well. Kilbridge et al. reported a widely varied PPV, ranging from 0.00 to 0.67. The rule 
efficiency varied between 0.00 and 0.21. The highest PPV values were found for rules 
detecting ADEs (e.g. antidote order). The rules detecting evolving unsafe situations had lower 
PPV [23]. We did not use clinical rules triggering on antidote orders. Comparable numbers 
for PPV are found in the study by Silverman et al. The rule efficiency varied between 0.05 
and 0.13. The authors determined that a realistic goal for created rules was a rule efficiency 
of 0.10 and an idealistic goal a rule efficiency of 0.20 [19]. Our rule effectiveness and PPV of 
ADEAS were 0.10 and 0.08 respectively. In themselves, these are promising figures indeed, 
but these figures could be increased if appropriate measures, such as enlarging the sensitivity 
or specificity of our clinical rules, are taken.
Meaning of the study
The combination of rule effectiveness and PPV was highest for clinical rules based upon the 
basic CPOE medication safety alerts fine-tuned to high risk patients. The safety alerts in the 
CPOE are retrieved from the Dutch national drug database (the G-Standard). This database 
is used as a knowledge base for all pharmacy systems and CPOE systems within hospitals 
in The Netherlands. A problem with the safety alerts (drug–drug interactions, duplicate 
orders and overdosages) is that they are frequently overridden due to low specificity. The 
safety alerts also have low sensitivity [12,13]. In our own specifically designed set of clinical 
rules, we have fine-tuned these safety alerts to patients at risk of ADEs. For example, the 
safety alert for patients using the combination of a NSAID and ACE-inhibitors or ARBs is 
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most effective when considered in relation to the kidney function of the individual patient. 
In the basic CPOE a safety alert is always generated when the combination of the two drugs 
are prescribed. With ADEAS, the combination only generates an alert if the patient has a 
declined renal function (eGFR < 50 ml/min). This makes the drug–drug interaction alert 
more clinically relevant. ADEAS takes into account the renal function of the patient, where 
the basic CPOE does not. It is clear from this example that using ADEAS is preferred to 
using a basic CPOE only. Another example is a drug–drug interaction between a NSAID 
and a corticosteroid. The basic CPOE safety alert is generated always when both drugs 
are prescribed. ADEAS only generates an alert when a drug for ulcer prevention is absent. 
ADEAS takes into account the co-medication of the patient, while the CPOE does not. The 
use of this category of clinical rules improves the specificity of the alerts and therefore may 
help to decrease alert fatigue. That some other investigators have used this approach as well 
underlines the importance and usefulness of such an approach [24-26]. For example Seidling 
et al. suggests refining drug–drug interactions with statin-drugs by using an upper dose 
limit [25]. And Riedmann et al. searched for context factors, such as patient, prescriber/
ward or alert characteristics, to prioritize drug–drug interactions [24].
In our study the highest number of consult and advice were given following alerts from 
clinical rules related to laboratory values (risk categories 1 and 2). This is in line with the 
observations in two of our other studies that show that the clinical rules linking laboratory 
and pharmacy information improve the sensitivity of the medication surveillance [14,27]. 
Other investigations also show that clinical rules related to laboratory values are suitable 
clinical rules that offer good results in detecting and preventing ADEs [20,21,28-30]. In our 
study the clinical rules related to laboratory values generated more than 50% of the alerts. 
They can be considered as most useful and promising rules. But as mentioned before, for 
better performance the rule effectiveness and PPV should be increased.
In the future we should focus on clinical rules from the three risk categories 1, 2 and 5 
(‘clinical rules with a combination of pharmacy and laboratory data’ and ‘clinical rules based 
upon the basic CPOE medication safety alerts fine-tuned to high risk patients’) to enhance 
the performance of ADEAS.
Conclusion
In conclusion, the CDS system ADEAS can effectively be used in daily hospital pharmacy 
practice to select patients at risk of potential ADEs, but to increase its benefit for routine 
patient care and to increase efficiency, both rule effectiveness and PPV for the clinical rules 
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should be improved. Furthermore, clinical rules would have to be refined and restricted to 
those categories that are potentially most promising for clinical relevance, i.e. ‘clinical rules 
with a combination of pharmacy and laboratory data’ and ‘clinical rules based upon the 
basic CPOE medication safety alerts fine-tuned to high risk patients’.
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Adverse drug events (ADEs) occur frequently in hospitalized patients, can result in harm 
but can often be prevented [1]. Many different methods to prevent ADEs are recognized 
[2-4] and two preventive strategies are the focus of this thesis, namely 1) computerized 
physician order entry (CPOE) with clinical decision support system (CDSS), and 2) clinical 
pharmacist activities.
Although no randomized controlled trials have been performed, several investigations have 
shown that a reduction in ADEs can be reached through the use of CPOE with CDSS [5-7]. 
A Dutch study showed that implementation of a CPOE with basic CDSS reduces certain 
types of medication errors (such as dosing errors and administrative and procedural errors). 
This study did not demonstrate a direct effect on actual patient harm [8].
At our institution, Leiden University Medical Center, the site where we performed our 
studies, a CPOE with basic CDSS is in use since 2003. This system, named Medicator® 
(iSOFT Nederland, Leiden, The Netherlands), gives basic drug-drug interaction and drug-
dosing alerts to the physician while prescribing medication and can in that way prevent 
some medication errors and ADEs [9]. This is called conventional medication surveillance.
In the current thesis our hypothesis is that the use of a more advanced CDSS incorporating 
clinical rules can improve the indentification of patients at risk of ADEs. These clinical event-
monitoring systems can use any data available in electronic form to detect potential ADEs 
and risk situations. The clinical rules or algorithms are based on identifiers which search 
for specific medication orders, patient characteristics and/or laboratory values. In addition, 
hospital pharmacists can interfere to prevent ADEs and, as such, improve medication safety. 
The development of this system, named Adverse Drug Event Alerting System (ADEAS) 
is the basis of this thesis. We have chosen to combine our two fields of interest to prevent 
ADEs: CDSS for identifying patients at risk of ADEs and hospital pharmacist intervention 
focused on these specific patients at risk instead of participation on ward rounds.
In this part of this thesis we highlight and critically discuss the following aspects of our 
advanced CDSS ADEAS (Figure 8.1):
•	 Development and validation of the CDSS ADEAS (‘analytical validity’)
•	 Ability of ADEAS to detect patients at risk of ADEs (‘clinical validity’)
•	 Ability of ADEAS guided interventions by hospital pharmacists to prevent 
ADEs (‘clinical utility’)




First in chapter 3 we show that we successfully developed and validated an advanced CDSS 
ADEAS. ADEAS is based on Gaston software (Medecs, Eindhoven, The Netherlands), which 
is a guideline-based decision support framework. The definition of the clinical rules by a 
multidisciplinary team resulted in a comprehensive set of 121 clinical rules with a wide 
clinical coverage.
A strong aspect of our CDSS ADEAS is that it gathers information from more databases 
available in the hospital compared to our basic CDSS within the CPOE. Not only data 
regarding patient drug prescriptions and drug-drug interaction data from the Dutch drug 
database ‘G-standard’ (Z-Index BV, The Hague, The Netherlands) are gathered, but also data 
regarding patient laboratory values and other data from the electronic patient file (EPF), 
like age and weight. In particular the use of laboratory data is of added value in clinical rules 
[10]. Laboratory and pharmacy functions are closely related. Drug choice and dosing often 
depend on laboratory information such as therapeutic drug levels and biochemical and other 
physiologic parameters, such as renal function. Despite this relation between laboratory 



























and pharmacy, connection between their clinical information systems is often suboptimal 
or non-existent [10], as is the case in our CPOE with basic CDSS. ADEAS is a solution for 
this problem. The clinical rules in ADEAS can combine prescription and laboratory data. 
Indeed, several studies have demonstrated that drug-laboratory combinations are one of the 
best tools for identifying (potential) ADEs [11-14]. Types of ADEs that can be prevented by 
use of such clinical rules are for example: too high a dose of a drug in a patient who suffers 
from a declined renal function [15,16], prescribing potassium supplementation to patients 
despite high potassium levels [17] and lack of laboratory value monitoring (e.g. liver function 
tests) at the initiation of drug therapy [18].
Unfortunately other potential useful data from the EPF such as microbiology data and 
medical diagnosis were not included in the clinical rules in ADEAS, because coded data on 
those items were not available yet. Also laboratory results of (pharmaco)genetic tests can be 
of use in clinical rules. We suggest to make these data available in the future so we can also 
use them in ADEAS, resulting in more potential useful clinical rules.
Furthermore in chapter 3 we describe our structured methodology for defining the clinical 
rules. We used seven risk categories to create the clinical rules. These seven risk categories are:
1. Combination of biochemical laboratory values with the initiation of a drug
2. Combination of biochemical laboratory values or therapeutic drug monitoring 
values with the ongoing use of a drug
3. Combination of the use of a drug with the non-use of another drug, the 
latter indicated for the prevention of an ADE
4. Medication used to treat an ADE
5. Basic CPOE medication safety alerts fine-tuned to high risk patients
6. Safety alerts from inspection authority
7. Medication errors and high risk drug situations
A multidisciplinary team discussed all drugs and drug classes from the Dutch national 
formulary (Farmacotherapeutisch Kompas, College voor Zorgverzekeringen, Diemen, The 
Netherlands) to formulate clinical rules on the basis of these seven risk categories. Finally this 
resulted in incorporation of 121 clinical rules in ADEAS (appendix chapter 3). We choose 
this thorough method because we intended to build an advanced CDSS that, in time, can 
replace our conventional medication surveillance, the basic CDSS within the CPOE. The 
seven risk categories fully match with the concept to create clinical rules which search for 
evolving unsafe situations, except for risk category 4 (Medication used to treat an ADE). 
These rules detect situations in which an ADE has already occurred and harm cannot be 
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prevented anymore. Consequently we have deleted the clinical rules belonging to this risk 
category in current practice.
The development of the system itself was time-consuming and required considerable 
technical support. Currently available CPOE systems on the Dutch market are not integrated 
with sophisticated CDSS, and of the few CDSS available, like Gaston, none did match the 
exact specifications essential for the application we were aiming for. This is the reason why 
many technical adaptations were necessary. An important disadvantage of this is that it 
makes such a home-grown CDSS difficult to replicate and implement in other institutions. 
Nevertheless the concept is still very useful for other hospital pharmacies. Although similar 
computerized alert systems are developed in the United States [19] and Europe [20], they 
are not available in The Netherlands. Until now there was limited experience with the 
development of such systems within Dutch hospital pharmacies. Fortunately knowledge 
about CDSS and clinical rules in hospitals and at software manufacturers is growing.
A technical validation was necessary to establish wether the system works according to 
the specification and our expectations. A validation program was developed and written 
because there are no existing guidelines for validation of a CDSS like ADEAS. We choose 
three different methods for the validation of ADEAS: 1) by use of dummy patients in the 
CPOE, 2) testing ADEAS in an off-line test setting, and 3) behind-the-scene testing of 
ADEAS and manual check of the results with the EPF. These three validation methods 
were necessary to validate all aspects of the clinical rules; all used terminology items (drug, 
laboratory values, drug-drug interactions, and patient characteristics) and all the different 
structures (‘logic’ or ‘flow’) used to build a clinical rule in ADEAS. Because of the large 
number of clinical rules (121), the validation process was complex and time-consuming. 
However, it is a necessary investment to guarantee a good quality of the system. In the future 
new clinical rules which are built in ADEAS and use an already validated terminology item 
and an already validated structure can be used directly in clinical practice and don’t need 
a comprehensive validation. When new terminology items are used in a clinical rule, e.g. 
medical diagnosis or pharmacogenetic laboratory data, the rule has to be validated before 
it is used in clinical practice according to one of the three described validation methods.
Chapter 4, 6 and 7 describe different clinical studies in which we investigated the clinical 
validity and clinical utility of ADEAS. From these studies we have concluded that only a small 
number of the 121 clinical rules incorporated in ADEAS resulted in alerts. In this respect it 
would have been better to start with a smaller more clinically relevant set of clinical rules. 





drug class known with a high frequency of preventable ADEs. Different studies showed that 
drug classes often associated with ADEs are analgesics, antibiotics, cardiovascular agents and 
anti-coagulants [11,21-25]. Another possible strategy is to focus on clinical rules categories 
known to effectively select potential ADE situations. As mentioned before, several studies 
have demonstrated that drug-laboratory combinations are one of the best tools for identifying 
(potential) ADEs [12-14,26]. Following that strategy we would have developed a set of clinical 
rules only covering our risk category 1 (combination of biochemical laboratory values with 
the initiation of a drug) and risk category 2 (combination of biochemical laboratory values or 
therapeutic drug monitoring values with the ongoing use of a drug) instead of all seven risk 
categories. A simulation learns us that this would have resulted in a set of about 60 instead 
of 121 clinical rules. Even more specificly, an alternative interesting strategy is to primarily 
focus on drug dosing in patients who suffer from a declined renal function [15,16].
Resuming, “start low and go slow” would have been a better strategy to formulate the clinical 
rules, instead of our comprehensive method.
Clinical validity
To investigate the ability of ADEAS to detect patients at risk of ADEs, the ‘clinical validity’, 
we compared ADEAS with other detection methods. First in chapter 3 we performed a 
proof of principle test. In chapter 4 we compared ADEAS with our conventional medication 
surveillance, the basic CDSS within our CPOE, and in chapter 5 we compared ADEAS with 
manual chart review by a clinical pharmacist.
In chapter 4 the results of the retrospective and prospective comparison of ADEAS with 
our conventional medication surveillance, the basic CDSS within our CPOE, showed that 
ADEAS detects different kind of patients at risk of ADEs compared to the conventional 
medication surveillance method. This is a confirmation of the results which we found in 
the proof of principle test in which we retrospectively compared 13 clinical rules in ADEAS 
with our conventional medication surveillance (chapter 3). 
The safety alerts generated by the CPOE with basic CDSS are retrieved from the G-standard, 
which is a national drug information database. These are safety alerts regarding drug-drug 
interactions and drug-overdosing. ADEAS generates alerts regarding a declined renal 
function or other laboratory abnormalities, the absence of essential concurrent medication 
to protect the patient for ADEs, and for example the use of a gastrointestinal tube. Our 
clinical validity studies showed that, in particular, clinical rules related to unadjusted drug 
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dosages in patients who suffer from a declined renal function are important triggers for 
potential ADEs. This is in line with the findings of other investigators [14-16]. The added 
value of the new ADEAS system is also illustrated by the rule ‘opioid receptor agonist and no 
prescription for laxative’. This rule gave a high number of alerts, both in the retrospective and 
prospective studies, whereas this high risk situation is not detected using the conventional 
medication surveillance method.
Also, the added value of the new ADEAS system is illustrated by a clinical rule regarding the 
prescription of a NSAID in a patient with a risk factor for ulcer-related bleeding and without 
a prescription for a proton pump inhibitor. The conventional medication surveillance system 
does generate an alert in for example a patient with the combination of a NSAID and a SSRI 
or corticosteroid. But in contrast to ADEAS the basic CDSS within the CPOE cannot take 
into account the age of the patient or the concurrent medication. Thus even if the patient 
uses a proton pump inhibitor the physician receives a safety alert. In this situation the basic 
CDSS within the CPOE generates many false positive alerts, which may lead to alert fatigue 
by the physician [27,28]. ADEAS only generates an alert when a proton pump inhibitor is 
absent and the patient is over the age of 70.
It is obvious that ADEAS has an added value in detecting patients at risk of potential ADEs 
compared with the conventional medication surveillance. However, we should realize that 
not all safety alerts from the G-standard are built in ADEAS. We did not create clinical rules 
regarding overdosing covering all drugs and we did not incorporate all drug-drug interactions 
from the G-Standard. This means that the two systems are used concurrently for the time 
being: the basic CDSS within the CPOE for overdosing alerts and some basic drug-drug 
interaction alerts and ADEAS for the fine-tuned clinical rules. Our primary goal for the 
future is to integrate both systems. By doing so we should realize that the clinical validity 
of the alerts generated by the G-Standard are assessed by a different method compared to 
the clinical validity of ADEAS [29]. 
There are many methods for the detection of (potential) ADEs, but none is considered 
the golden standard. ADEs were originally detected by means of voluntary report and 
chart review [21,25]. With the aid of modern information technology, computer-based 
monitoring systems, such as basic CDSS within the CPOE and systems such as ADEAS, 
have become more prominent detection methods [12,23,30,31]. With both manual chart 
review and computer-generated signals high rates of ADEs can be found [32]. On the other 
hand, voluntary report is still considered to be the method of choice for permanent error 





not the best strategy to detect patients with ADEs, because of the risk of underreporting. 
That is why we choose to compare ADEAS with our current daily practice (conventional 
medication surveillance) as golden standard in the proof of principle test and in the study 
in chapter 4. In addition we compared ADEAS in a smaller setting with chart review in 
chapter 5 because it is more labour intensive. In this  study in chapter 5 the comparison of 
a set of 16 clinical rules from ADEAS with manual pharmacist medication review revealed 
that a considerable proportion of the medication errors (dosing errors and therapeutic 
errors) detected by chart review are also detected by the clinical rules.
Following the results of the clinical validity studies we can conclude that ADEAS is able to 
detect patients at risk of ADEs and that this method is a useful addition to the conventional 
medication surveillance, a basic CDSS within our CPOE.
Clinical utility
The goal of ADEAS is to prevent harm and to enable clinical pharmacists to make corrective 
interventions guided by alerts from ADEAS. The extent in which ADEAS with clinical 
rules can actually prevent ADEs, the ‘clinical utility’, is investigated in chapter 6. This 
investigation showed that the use of ADEAS and subsequent interventions by the hospital 
pharmacist resulted in a 37% relative risk reduction for possible or definitely preventable 
ADEs. Other investigations also showed that the use of CPOE and CDSS can reduce ADEs 
[5-7]. In their review, Ammenwerth et al. described six studies with a 35% to 98% relative 
risk reduction for potential ADEs and four studies with a 30% to 84% relative risk reduction 
for ADEs. The CPOE/CDS systems in these studies varied between no CDSS (only CPOE), 
limited CDSS or advanced CDSS [5]. It is difficult to compare the effect of ADEAS with 
other investigations, because most studies investigating the effect of CPOE and CDSS on 
medication errors and ADEs differ substantially in their setting, type of system (home-grown 
or commercial), design, quality and consequently their results. Many studies, like ours, 
have the same limitations regarding for example the comparability between intervention 
and comparison group, no adjustment for confounding factors or use of lower level study 
designs and the chosen detection method for ADEs [5]. To partly resolve this problem, 
recently several guidelines for health informatics evaluation studies has been published, for 
example the STARE-II guidelines [33].
We have not investigated the isolated effect of ADEAS on prevention of ADEs, but we have 
investigated the effect of ADEAS combined with interventions by the hospital pharmacist. 
Two other investigations studying the effect of pharmacist intervention found a higher 
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reduction in preventable ADEs. Leape et al. found a 66% reduction in the ICU setting and 
Kucukarslan et al. found a 78% reduction in a general internal medicine unit [34,35]. In 
these two studies the pharmacist participated on ward rounds. Regarding the role of the 
hospital pharmacist, more studies have shown that participation of clinical pharmacist with 
healthcare teams on patient rounds indeed resulted in improved care and this method is also 
suggested as one of the methods to prevent ADEs [33,36,37]. Our intention was to encourage 
hospital pharmacist interventions focused on high risk patients, detected by our advanced 
CDSS using clinical rules. We did not participate on ward rounds because of limited capacity.
In three studies (chapter 4, 6 and 7) we reviewed the interventions made by the hospital 
pharmacist following alerts from ADEAS. In the prospective comparative study between 
ADEAS and the conventional medication surveillance (chapter 4), the hospital pharmacist 
made more interventions with a higher acceptance percentage following alerts from ADEAS 
compared to alerts from the conventional medication surveillance method. A limitation 
of this prospective study was that it was conducted on a small internal medicine ward. 
Consequently the absolute intervention and acceptance rate numbers were low. In chapter 
6 and 7 the absolute intervention numbers were considerably higher. The studies in these 
two chapters were conducted on five hospital wards. Our intervention percentage varied 
between 9% (chapter 6), 10% (chapter 7) and 19.4% (chapter 4). This percentage of safety 
alerts, resulting in an advice or intervention by the hospital pharmacist, may seem low, but is 
comparable or even higher than in other international investigations. Jha et al. investigated 
a commercial computerized surveillance system and found that in 11.3% reviewed alerts 
the physician was contacted [38]. Kilbridge et al. evaluated 4604 triggers from a computer-
based ADE surveillance system with rules of which 4% led to an intervention [39]. The 
intervention percentages found by Silverman et al. with their computer-based monitoring 
system with rules ranged from 5 to 13% [26].
When we compare our intervention acceptance rates, 41% (chapter 6), 63% (chapter 7) 
and 71% (chapter 4), with acceptance rates found in other studies, our rates are lower. 
Two studies in which pharmacists gave dosages advices in case of impaired renal function 
showed an acceptance rate of 74% and 88% respectively [15,16]. In addition the study 
of Silverman et al. with his computer-based system reports an acceptance rate of 78.7%, 
90.9% and 92.2% in their 3 different study periods [26]. When looking at studies regarding 
pharmacist participation on ward rounds, the before mentioned study of Leape et al. in 
the ICU found a 99% acceptance rate [35]. Similarly, the study of Kucukarslan et al. on a 
general medicine unit documented an acceptance rate of 98% [34]. An explanation could be 





almost all interventions were made by phone, but in chapter 4, with a higher acceptance 
rate, most interventions were made by ward visit. Because of the small absolute numbers 
we cannot make solid conclusions at this point, but it is important not to underestimate 
ward visits, although they are more time-consuming in general. Thus by selecting patients 
at risk of potential ADEs, and making goal-oriented visits to the ward, the pharmacist can 
be more time-efficient than by routinely participating on ward rounds.
Future perspectives of ADEAS and clinical rules
In our three clinical utility studies (chapter 4, 6 and 7), we found that a relatively small 
number of the clinical rules active in the system ADEAS resulted in alerts. Chapter 7 showed 
that the overall rule effectiveness and positive predictive value (PPV) of ADEAS is low 
(0.10 and 0.08 respectively). In chapter 6 the overall rule effectiveness and PPV were 0.09 
and 0.07 respectively. When we recalculate the number the same way for the prospective 
study in chapter 4 we can estimate an overall rule PPV for ADEAS of 0.06. This means 
that 9-10% of the safety alerts generated with ADEAS resulted in a contact moment by the 
hospital pharmacist with the physician or nurse and that 6-8% of the alerts resulted in an 
advice or intervention to prevent a possible ADE. This does not automatically imply that 
most of the alerts are useless. These alerts can indeed indicate a potential ADE situation, 
but in specific patient cases the alert can be rated as ‘non-relevant’, after review and check 
of EPF in detail. The alert can therefore be considered useful as it does lead to a medication 
check by the pharmacist, but does not result in an intervention or contact moment. A few 
of such situations are explained in more detail in the discussion of chapter 7. All of these 
explained reasons are related to the low sensitivity or low specificity of several clinical rules 
in ADEAS. In some cases the clinical rules were adapted during the studies to increase 
their sensitivity or specificity. Adapting the content of the rules during use is an acceptable 
way to improve the PPV for the clinical rules [26]. To lower the number of ‘non-relevant’ 
alerts we aim to increase the rule effectiveness and PPV of ADEAS in the near future. One 
strategy is to add more sub items to a clinical rule. For example the sub item ‘drug dosage’ 
can be added in a rule regarding drug use and a declined renal function. Incorporating a 
cut-off dose under which no action is required and thus no alerts are generated can make 
the rules more efficient. In addition, the sub items ‘ward’ or ‘specialty’ can be added in 
a rule not relevant for a specific patient category. Some other investigators have already 
suggested a similar approach which underlines the importance and usefulness of such a 
strategy [40-42]. For example Scheidling et al. suggested to refine drug-drug interactions 
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with statin-drugs by using an upper dose limit [41]. In addition, Riedmann et al. searched 
for context factors, such as patient, prescriber/ward or alert characteristics, to prioritize 
drug-drug interactions [40]. Duplicate alerts are also a problem. These arise when the 
potential ADE situation keeps on existing, while for example already has been agreed on 
that the potential ADE situation is not harmful for this specific patient. Consequently a 
smart way to lower the number of duplicate alerts has to be created. A sub item looking 
at the previous generated alert with that clinical rule in the same patient might be added 
to the rule. 
The rule effectiveness and PPV number between the categories of clinical rules was highly 
variable in our studies, a finding which is often observed in the literature. Kilbridge et al. 
reports a widely varied PPV for their rules, ranging from 0.00 to 0.67. The rule efficiency 
varies between 0.00 and 0.21. The highest PPV values are found for rules detecting ADEs 
(e.g. antidote order). Rules with evolving unsafe situations had lower PPV [39]. Comparable 
numbers for PPV are found in the study of Silverman et al.; their rule efficiency varied between 
0.05 and 0.13. They suggested that a realistic goal is a rule efficiency of 0.10 and an idealistic 
goal a rule efficiency of 0.20 [26]. This indicates that our results can be considered promising.
In our investigations the combination of rule effectiveness and PPV was highest for clinical 
rules based upon the basic CPOE medication safety alerts fine-tuned to high risk patients 
(risk category 5, see for details chapter 3 and 7). Most consults and advices are given following 
alerts from clinical rules related to laboratory values (risk category 1 and 2, see for details 
chapter 3 and 7). These three risk categories together cover 95 clinical rules. The first step 
to adapt ADEAS in the near future can be to narrow our clinical rules set to these three risk 
categories. These rules are most promising to improve the performance of ADEAS and to 
optimize the benefit for routine patient care.
A limitation of our research is that we have not studied cost-effectiveness of the application 
ADEAS and the interventions of the hospital pharmacists. Time and cost aspects are obviously 
very relevant subjects for implementation novel methods for medication surveillance. It is our 
experience that developing, building, validating and supporting a system such as ADEAS is 
very time-consuming and very costly. Are all the time and money efforts in balance with the 
medication safety profit it brings us? We cannot give an answer to that important question 
with the studies in this thesis and this remains a challenging pharmaco-economic issue for 
future investigation.
ADEAS is developed as a pharmacy decision support system and not as a CDSS within the 





prescribing physician. The reason for this is that we believe that pre-screening of safety alerts 
by the pharmacist is useful to prevent alert fatigue with the physician [19,43]. In our studies 
we indeed see a large difference between the number of alerts compared to the number 
of intervention and advices. A review from Van der Sijs et al. described that in more than 
half of all cases, physicians ignore safety alerts. This can lead to error producing situations; 
the physician may not recognize a really clinical relevant and important alert in all cases 
[27]. Another study from Van der Sijs et al. indeed showed that safety alerts from a basic 
CDSS within a CPOE, similar as we use in our hospital, were frequently overridden [44]. 
Medication surveillance is the core business of the pharmacist, and it is suggested that the 
prescribers’ knowledge of potential clinically relevant drug-drug interactions is limited in 
general [45]. Another argument to use ADEAS primarily as a pharmacy decision support 
system was that we wanted to use ADEAS as a tool for the hospital pharmacist for more 
clinical ward-based activities. This goal is not completely accomplished. Our ward-based 
activities have not substantially grown since the introduction of ADEAS. Thus for future 
perspective we have to find a way to enlarge clinical activities by use of ADEAS.
For the near future we suggest to distinguish three different objectives for our clinical rules:
1. Clinical rules as daily medication safety alerts for the hospital pharmacist.
These are safety alerts that do not need immediate action by the physician 
and are pre-screened by the hospital pharmacist. These safety alerts can be 
generated in the hospital pharmacy daily. This way of using clinical rules 
was subject of research in this thesis.
2. Clinical rules as daily medication safety alerts for the physician.
These are safety alerts that need immediate action by the physician. These 
safety alerts can be generated online while prescribing medication within 
the CPOE. For this goal ADEAS and our CPOE have to be integrated.
3. Clinical rules that can be used as periodic medication review tool by the hospital 
pharmacist.
These are safety alerts that can be used for the review or screening of 
medication to optimize pharmacotherapy for example in long stay facilities, 
during weekly ward rounds, or at discharge. Also this can be safety alerts that 
focus on one specific issue e.g. costs or efficiency (for example all patients 
with three or more days of intravenous antibiotic therapy). These safety 
alerts can be generated on demand for one specific patient or one specific 
rule. These alerts are probably more suited for ward-based activities.
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In this thesis we investigated our own developed and built (‘home-grown’) CDSS ADEAS, 
based on Gaston, and compared it only with one other basic CDSS within a CPOE 
(Medicator). The fact that these systems are not used in all hospitals in The Netherlands 
does not mean that our results are not relevant for a larger public. The concept of the clinical 
rules, validation issues, how to create better PPVs, is applicable for all (hospital) pharmacies 
in The Netherlands (and abroad) who have started or aim to start to use clinical rules. The 
use of clinical rules in Dutch hospital pharmacy practice is growing [46-50] and it is useful 
to share information and to learn from these practices. This thesis is one of the first reports 
that gives a total overview of experience with the development of a CDSS with clinical rules 
and its use in the hospital pharmacy setting.
Also on a national level the importance of clinical rules is recognized. The Dutch Hospital 
Pharmacists Association (Nederlandse Vereniging van Ziekenhuisapothekers, NVZA) has 
initiated a working group ‘Clinical rules’ which recently has published a starting document on 
how to use clinical rules and a start set of 10 different clinical rules (http://www.kennisplein-
nvza.nl/thema_s/fpz/clinical_rules). Also the Royal Dutch National Pharmacists Association 
(Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, KNMP) has initiated 
a multidisciplinary expert-group for clinical rules (expert-groep Medisch-Farmaceutische 
Beslisregels). The task of this group is to formulate clinical rules on specific topics for 
community pharmacists, general practitioners, hospital pharmacist and medical specialists 
in the hospital. In the future these clinical rules will be tested by the software companies of 
the different pharmacy information systems in The Netherlands, and thus will turn out to 
be standard for all pharmacies in the country. The future policy (2013-2017) of The Dutch 
Hospital Pharmacists Association focuses on pharmaceutical patient care throughout the 
entire stay of the patient within the hospital or care facility. Clinical rules are incorporated 
as a part of the practice of pharmaceutical care within this policy. Besides, the use of clinical 
rules within the hospital is a quality performance indicator within the Dutch program of 
Zichtbare Zorg (ZIZO) pharmacy.
Finally our future goals and activities regarding ADEAS and clinical rules will enhance the 
following subjects:
•	 To guarantee the quality and to secure the performance of ADEAS
•	 To integrate the two systems, ADEAS and the conventional medication 
surveillance, within one system






•	 To narrow the current set of clinical rules by focusing on three main risk 
categories:
 - Combination of biochemical laboratory values with the initiation of a drug
 - Combination of biochemical laboratory values or therapeutic drug 
monitoring values with the ongoing use of a drug
 - Basic CPOE medication safety alerts fine-tuned to high risk patients
•	 To enlarge rule effectiveness and PPV of the clinical rules
•	 To adapt our clinical rules to the three main targets:
 - Clinical rules as daily medication safety alerts for the hospital pharmacist
 - Clinical rules as daily medication safety alerts for the physician
 - Clinical rules that can be used as periodic medication review screening 
tool by the hospital pharmacist
•	 To define new clinical rules covering for example our special interest topic 
pharmacogenetics
•	 To enhance ward visits
Clinical rules will definitely remain and this thesis hopefully contributes to the optimal use 
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Drug use is common but in addition to positive effect it can also lead to unwanted effects. 
Adverse drug events (ADE) refer to any injury resulting from the use of a drug. ADEs can 
be due to a medication error or an adverse drug reaction (side effect of a drug). Medication 
errors can be prevented most of the time. Adverse drug reaction on the other hand cannot 
always be prevented.
ADEs occur frequently in hospitalized patients. A substantial proportion of these ADEs are 
considered preventable. These are mostly ADEs caused by a medication error. The literature 
describes different methods to prevent ADEs. For example barcoding of drugs and patients, 
intravenous admixture units for patient care and computerized physician order entry (CPOE) 
instead of handwritten paper recipes. Obviously, each method interacts in a particular part 
of the drug distribution chain, from prescribing, dispensing to drug use. In this thesis two 
methods are described, namely 1) CPOE with clinical decision support system (CDSS) and 
2) clinical pharmacist activities.
At our institution, Leiden University Medical Center (LUMC), a CPOE with basic CDSS 
is in use since 2003. This CPOE system gives basic drug-drug interaction and drug dosing 
alerts to the physician while prescribing medication and can in that way prevent some 
medication errors and ADEs. This is called conventional medication surveillance. Our 
hypothesis is that the use of a more advanced CDSS incorporating clinical rules can improve 
the identification of patients at risk of ADEs. These clinical event-monitoring systems can 
use any data available in electronic form to detect potential ADEs and risk situations. The 
clinical rules or algorithms are based on identifiers which search for specific medication 
orders, patient characteristics and/or laboratory values. In addition, hospital pharmacists 
can interfere to prevent ADEs and, as such, improve medication safety. We have chosen to 
combine two strategies to prevent ADEs: CDSS for identifying patients at risk of ADEs and 
hospital pharmacist intervention focused on the specific patients at risk.
The aim of this thesis is 1) to develop a CDSS with clinical rules for use in the hospital 
pharmacy to identify patients with potential ADEs and 2) to investigate the ability of this 
system to identify these patients at risk of ADEs and finally 3) to investigate if these potential 
ADEs can be prevented by interventions by the hospital pharmacist. All of these studies 
focus on the hospitalized patient.
This thesis is divided in five parts. The first part, the introduction, starts with a comprehensive 





ADEs (chapter 2). In this review two strategies of prevention, pharmacist participation on 
ward rounds and CPOE with CDSS are highlighted. Moreover, two promising CDSS are 
discussed in more detail, namely computer-based monitoring systems and information 
systems which link laboratory and pharmacy data. The second part describes the 
development and the validity tests of our home-grown CDSS (analytical validity). In the 
third and fourth part of this thesis the clinical validity and clinical utility of the new system 
is discussed. The fifth part contains the general discussion and a future outlook.
Analytical validity
Chapter 3 describes the development and validation of the CDSS with clinical rules aimed to 
identify patients at risk of ADEs. The system is named Adverse Drug Event Alerting System 
(ADEAS). ADEAS is based on Gaston software (Medecs BV, Eindhoven, The Netherlands), 
which is a guideline-based decision support framework, consisting of both a guideline 
development module and a decision support module. The guideline development module 
describes the structure (flow) of the guideline by means of knowledge or data available in 
electronic form, such as data on drug prescription, laboratory values, patient characteristics 
and drug-drug interactions. The decision support module was used to link Gaston with our 
hospital information system, CPOE and the Dutch drug information database G-Standard 
(Z-Index, The Netherlands) in order to import the required information and to execute the 
clinical rules. The content of the clinical rules was defined with the help of a multidisciplinary 
team. From a drug perspective seven risk categories were identified, which were used to 
create the clinical rules: 
1. Combination of biochemical laboratory values with the initiation of a drug 
example: patient starts with vancomycin and renal function is not known
2. Combination of biochemical laboratory values or therapeutic drug monitoring 
values with the ongoing use of a drug
example: patient uses gentamycin and no therapeutic drug monitoring
3. Combination of the use of a drug with the non-use of another drug, intended 
to prevent an ADE
example: patient with chronic use of opioid receptor agonist and no prescription 
of laxative
4. Medication used to treat an ADE
Summary
152
5. Basic CPOE medication safety alerts fine-tuned to high risk patients 
example: patient (> 60 yr) with NSAID prescription but no prescription of 
proton pump inhibitor for protection of stomach ulcer
6. Safety alerts from inspection authority or drug companies
7. Medication errors and high risk drug situations
A total of 121 clinical rules with a wide clinical coverage were built into the system. After 
building the clinical rules into ADEAS, we performed a technical validation of the system. 
A technical validation is necessary to establish whether the system works according to the 
specification and our expectations. A validation program was developed and written, because 
there are no existing guidelines for validation of a CDSS such as ADEAS. We choose three 
different methods for the validation of ADEAS: 1) by use of dummy patients in the CPOE, 
2) testing ADEAS in an off-line test setting, and 3) behind-the-scene testing of ADEAS and 
manual check of the results with the electronic patient file (EPF).
The development and validation of ADEAS was time-consuming but eventually we managed 
to successfully develop a CDSS for us in the hospital pharmacy.
Clinical validity
To investigate the ability of ADEAS to identify patients at risk of ADEs we have compared 
ADEAS with other ADE detection methods. First in chapter 3 we have performed a proof 
of principle test. In this study we retrospectively compared the alerts of a set of 13 clinical 
rules in ADEAS with the alerts from our conventional medication surveillance during a 
3-day period. The conventional medication surveillance consists of basic CDSS alerts (drug-
dosing alerts and drug-drug interaction alerts) that are visible online for the physician while 
ordering medication within the CPOE. The proof of principle test showed that ADEAS is 
potentially useful and is complimentary to the conventional system. ADEAS generated 
alerts and detected additional risk situations, which were not generated by conventional 
medication surveillance.
Chapter 4 describes a retrospective and a prospective comparison of ADEAS with the 
conventional medication surveillance. In these two studies all 121 clinical rules in ADEAS 
were active. The retrospective comparison of ADEAS was conducted on all patients admitted 
to the hospital (except patients admitted on intensive care unit) during a 1-month period. 





conventional medication surveillance method. The prospective comparison between the 
new ADEAS system and the old medication surveillance system was performed during a 
6-month period. All patients admitted to one general internal medicine ward were included. 
Every day ADEAS searched for risk situations in the EPF of the patients and generated alerts. 
Following the alerts the hospital pharmacist could give advice to the physician or nurse 
to prevent a detected potential ADE. The alerts from both systems were compared daily. 
ADEAS generated 248 alerts during the 6-month study period whereas the conventional 
medication surveillance generated 177 alerts. Following the alerts from ADEAS the hospital 
pharmacist made 14 interventions compared to 5 interventions following the alerts from the 
conventional system. The type of risk patient identified by ADEAS was different compared 
to the conventional medication surveillance. The conventional medication surveillance 
generated safety alerts regarding drug-drug interactions and drug overdosing. ADEAS 
generated alerts regarding a declined renal function and the use of medication, which needed 
dose reduction, and the absence of essential concurrent medication.
In chapter 5 the results of ADEAS are compared with manual medication review by a 
pharmacist. Manual chart review is a well-known method to search for ADEs. The alerts 
from ADEAS, with 16 clinical rules active, were compared with therapeutic medication errors 
found by manual chart review. ADEAS detected 39% of the medication errors found with 
chart review. A combination of ADEAS together with conventional medication surveillance, 
a basic CDSS within a CPOE, detected 66% of the medication errors.
Following the results of the clinical validity studies we can conclude that ADEAS is able to 
identify patients at risk of ADEs and that this method is a useful addition to the conventional 
medication surveillance.
Clinical utility
The goal of ADEAS is to prevent harm and to enable hospital pharmacists to make corrective 
interventions guided by alerts from ADEAS. 
Chapter 6 describes the investigation of the extent to which ADEAS based interventions 
by hospital pharmacists can prevent ADEs in the elderly patient (> 65 years of age) with 
polypharmacy (> 5 drugs). Before implementation of ADEAS only conventional medication 
surveillance was present. After implementation of ADEAS both methods were used to select 
risk situations. ADEAS was run every night and the following morning hospital pharmacists 
collected all generated alerts. Subsequently additional case specific information for each 
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patient was collected by the hospital pharmacist. If necessary the hospital pharmacist made 
an intervention to prevent the potential ADE. The number of ADEs was compared before 
and after the introduction of ADEAS. Retrospectively all charts of the included patients 
were searched for ADEs by manual chart review. The detected ADEs were subdivided in 
preventable and not preventable ADEs. In the period before use of ADEAS 42 preventable 
ADE were found by manual chart review in 240 hospital admissions. After implementation 
of ADEAS 27 preventable ADEs were found in 248 hospital admissions. We calculated a 
relative risk reduction of 37%. Many studies that investigate ADEs, ours included, have 
limitations regarding for example the comparability of the intervention and comparison 
group, the design of the study, possible confounding factors and the selected detection 
method for ADEs. But overall we can conclude that ADEAS based interventions by the 
hospital pharmacist can reduce the number of ADEs compared to the use of conventional 
medication surveillance alone.
In chapter 7 we describe our experience with the daily use of ADEAS in hospital pharmacy 
practice. In addition to the evaluation of the ADEAS system, also the assessment of the 
rule effectiveness and the positive predictive value (PPV) of the clinical rules was studied. 
During the 5-month study period ADEAS generated 2650 safety alerts in a total of 931 
patients admitted to the hospital. In 270 alerts (10%) the hospital pharmacist contacted 
the physician or nurse and in 204 cases this led to an advice to prevent a possible ADE. A 
measure of rule effectiveness is the ratio of the number of alerts resulting in contact with 
the healthcare professional to the total number of alerts generated by ADEAS. The overall 
rule effectiveness was 0.10. The PPV was calculated from the quotient of the number 
of interventions to prevent a possible ADE and the total number of alerts generated by 
ADEAS. The overall PPV was 0.08. Most alerts were generated with clinical rules from the 
categories linking pharmacy and laboratory data (risk category 1 and 2). Combination of 
rule effectiveness and PPV was highest for clinical rules based upon risk category ‘basic 
CPOE medication safety alerts fine-tuned to high risk patients’. In that case rule effectiveness 
was 0.17 and the PPV was 0.14. 
The conclusion of the results in chapter 7 is that ADEAS can effectively be used in daily 
hospital pharmacy practice to identify patients at risk of potential ADEs, but to increase 
the benefits for routine patient care and to increase efficiency, both rule effectiveness and 






In the last part of this thesis, chapter 8, the development of ADEAS and the clinical rules, 
the ability of the system to identify patients at risk of potential ADEs and to prevent these 
ADEs is discussed and put in perspective. This chapter also describes our ideas for future 
use of clinical rules in hospital (pharmacy) practice to identify risk patients, to prevent ADEs 
and ultimately to make drug use safer for our patients.
Summarizing, the development of ADEAS was successful, but it would have been a better 
strategy to start with a smaller set of clinical rules instead of our comprehensive set with 
a wide clinical coverage. An alternative strategy would be to start with the most effective 
clinical rules, those belonging to risk category 1, 2 and 5. With a smaller set of clinical rules 
the development and validation process would have been less time-consuming.
A strong aspect of ADEAS is that it combines data from different databases available in the 
hospital information system. In particular the use of laboratory data is of added value in 
clinical rules. Also the absence of essential concurrent medication can be found through 
ADEAS. This is in contrast to the conventional medication surveillance, which cannot detect 
these situations. Examples of useful safety alerts based on clinical rules are: 1) patient with 
vancomycine therapy and absence of blood monitoring for vancomycine concentration, 
2) too high a dose of a drug in a patient who suffers from a declined renal function and 3) 
patient with chronic opioid use and no laxative therapy. ADEAS generates alerts in evolving 
unsafe situations and can in this way help to prevent harm from an ADE. This is in contrast 
with older computerized alert systems that generate an alert for example when the physician 
prescribes an antidote. But in that case harm already has occurred and consequently cannot 
be prevented anymore.
For future use our goal is to improve rule effectiveness and positive predictive value. At 
this moment ADEAS generates too many false positive alerts; alerts that do not require any 
action. For example ADEAS generates an alert when a patient has a declined renal function 
and uses ciprofloxacin. The hospital pharmacist checks the dose of the drug in the CPOE 
and concludes that the physician correctly adapted the dose to the declined renal function. 
This kind of safety alert does not lead to an intervention by the hospital pharmacist, but 
is still a useful alert. In the future the clinical rules can be optimized by adding a sub item 
regarding the dose of the drug, so it becomes more clinical relevant. For now ADEAS is used 
in the hospital pharmacy. In the future we would like to integrate ADEAS within our CPOE, 
so safety alerts can also be generated real-time online for the prescribing physician. Before 
this can be realized the percentages of false positive alerts must be acceptably low. If the 
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percentage of false positive alerts is too high there is a risk of alert fatigue. This means that the 
physician can miss a real import safety alert with the possible consequence of patient harm. 
For the future we suggest distinguishing three different objectives for our clinical rules:
1.  Clinical rules as daily medication safety alerts for the hospital pharmacist
2.  Clinical rules as daily medication safety alerts for the physician
3.  Clinical rules that can be used as periodic medication review tool by the 
hospital pharmacist
Our future goals and activities regarding ADEAS and clinical rules will focus on the 
integration of the two systems ADEAS and the conventional medication surveillance. We 
should guarantee the quality and secure the performance of ADEAS. And we must not 
forget our clinical pharmacy activities, thus another future goal is to enhance ward visits.
In this thesis we have investigated our self-developed and built home-grown CDSS ADEAS. 
LUMC is one of the first hospital pharmacies who have adopted the concept of clinical 
rules. This thesis can contribute to optimal use of clinical rules in hospital pharmacy 
practice. Both The Dutch Hospital Pharmacists Association (Nederlandse Vereniging van 
Ziekenhuisapothekers, NVZA) and the Royal Dutch National Pharmacists Association 
(Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, KNMP) support 
the importance of the use of clinical rules. Clinical rules will definitely remain and will 





Geneesmiddelen worden veel gebruikt voor het bestrijden of voorkomen van ziektes en 
symptomen, maar naast het gewenste effect kunnen geneesmiddelen ook tot schade leiden. 
Deze neveneffecten door het gebruik van geneesmiddelen worden in het Engels ‘adverse 
drug events’ (ADEs) genoemd. ADEs kunnen worden veroorzaakt door de werking van 
het geneesmiddel zelf, dit wordt bijwerking genoemd, of door het foutief gebruik van het 
geneesmiddel, ook wel medicatiefout genoemd. Medicatiefouten kunnen vaak voorkomen 
worden; bijwerkingen niet altijd.
ADEs treden regelmatig op bij patiënten die opgenomen zijn in het ziekenhuis. Een deel 
van deze ADEs wordt als vermijdbaar beschouwd. Dit zijn met name ADEs veroorzaakt 
door medicatiefouten. Er zijn verschillende methoden in de wetenschappelijke literatuur 
beschreven waarmee ADEs mogelijk verminderd of voorkomen kunnen worden. Voorbeel-
den zijn o.a. barcode scannen van geneesmiddelen en patiënten, speciale bereidingsunits op 
de verpleegafdeling voor het voor toediening gereed maken van intraveneus toe te dienen 
geneesmiddelen en het voorschrijven van geneesmiddelen via een elektronisch voorschrijf 
systeem (EVS) in plaats van op een handgeschreven papieren recept. Elke methode heeft 
invloed op een deel van het geneesmiddeldistributieproces, van voorschrijven, leveren en 
klaarmaken tot toedienen. In dit proefschrift komen 2 methodes aan bod, namelijk 1) het 
gebruik van een klinisch beslissingsondersteunend computersysteem als toevoeging aan 
het EVS voor medicatie in het ziekenhuis en 2) interventies door de ziekenhuisapotheker.
In het Leids Universitair Medisch Centrum (LUMC) wordt bij het voorschrijven van ge-
neesmiddelen gebruik gemaakt van een EVS. Tijdens het elektronisch voorschrijven van 
geneesmiddelen krijgt de arts automatisch meldingen met betrekking tot overdoseringen 
en geneesmiddelinteracties te zien. Deze standaard medicatiebewaking kan al een aantal 
ADEs voorkomen. Wij denken dat een meer geavanceerde medicatiebewaking door middel 
van het gebruik van een klinisch beslissingsondersteunend computersysteem een toege-
voegde waarde heeft om nog meer ADEs te voorkomen. Zo’n systeem maakt gebruik van 
medisch farmaceutische beslisregels, in het Engels ‘clinical rules’ genaamd. Dit zijn vooraf 
gedefinieerde algoritmes gebaseerd op een combinatie van gegevens uit het elektronisch 
patiëntendossier, zoals geneesmiddelgebruik, (klinisch-chemische) laboratoriumwaarden 
en patiëntkarakteristieken. Met behulp van deze clinical rules worden patiënten met een 
mogelijk risico op een ADE opgespoord. Vervolgens kan de ziekenhuisapotheker contact 





Het doel van dit proefschrift is om 1) een klinisch beslissingsondersteunend systeem 
te ontwikkelen voor gebruik in de ziekenhuisapotheek om patiënten met een risico op 
een ADE op te sporen, vervolgens 2) te onderzoeken of dit systeem ook daadwerkelijk 
relevante risicopatiënten opspoort en 3) te onderzoeken of de mogelijke ADEs die opge-
spoord worden door het systeem ook voorkomen kunnen worden door interventies door 
de ziekenhuisapotheker.
Dit proefschrift bestaat uit vijf delen. Het eerste deel, de introductie, omvat een algemene 
inleiding in hoofdstuk 1 en een uitgebreid literatuuronderzoek in hoofdstuk 2 waarin diverse 
methodes om ADEs te voorkomen worden beschreven. In het literatuuronderzoek wordt 
ingezoomd op klinisch beslissingsondersteunende computersystemen met clinical rules als 
methode om ADEs te voorkomen en dan met name de connectie tussen geneesmiddelgebruik 
en de laboratoriumwaarden van de patiënt. Het tweede deel beschrijft de ontwikkeling en 
validatie van ons eigen klinisch beslissingsondersteunend systeem (analytische validiteit). 
Het derde en vierde deel van dit proefschrift bevatten respectievelijk onderzoeken naar de 
klinische validiteit en de klinische toepasbaarheid van het nieuwe systeem. Het vijfde deel 
bevat een discussie van het in het proefschrift beschreven werk en een beschouwing van 
toekomstige ontwikkelingen.
Analytical validity
Hoofdstuk 3 beschrijft de ontwikkeling en validatie van ons eigen klinisch beslissingson-
dersteunend systeem, genaamd ‘Adverse Drug Event Alerting System’ (ADEAS). ADEAS 
is samengesteld in Gaston software (Medecs BV, Eindhoven). Gaston bestaat uit een 
richtlijneditor waarin de clinical rules kunnen worden samengesteld en een beslissingson-
dersteunende module die communiceert met de diverse elektronische informatiesystemen 
en de beslisregel vertaalt in door de computer uit te voeren stappen. De systemen waaruit 
informatie wordt opgehaald zijn: geneesmiddelvoorschrijfgegevens uit het EVS, klinisch-
chemische laboratoriumwaarden en patiëntenkarakteristieken uit het elektronisch patiënten-
dossier en geneesmiddelengegevens en interacties uit de G-Standaard (Z-Index, Nederlandse 
geneesmiddeldatabase). De clinical rules zijn geformuleerd in een multidisciplinair team 
op basis van zeven risicocategorieën: 
1. Laboratoriumwaarden van de patiënt gekoppeld aan de start van een ge-
neesmiddel
voorbeeld: patiënt start met vancomycine zonder dat de nierfunctie bekend is
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2. Laboratoriumwaarden van de patiënt gekoppeld aan het gebruik van een 
geneesmiddel
voorbeeld: patiënt gebruikt gentamicine zonder dat de bloedspiegels gecon-
troleerd worden
3. Ontbreken van relevante beschermende comedicatie
voorbeeld: patiënt gebruikt chronisch opiaat pijnstiller zonder laxans
4. Geneesmiddel in gebruik voor de behandeling van een bijwerking van een 
ander geneesmiddel
5. Standaard geneesmiddelinteracties uit het EVS aangepast aan risicopatiënten 
voorbeeld: patiënt ouder dan 60 jaar met NSAID pijnstiller zonder maagbe-
scherming
6. Veiligheidssignalen van de inspectie en geneesmiddelenleveranciers
7. Veel voorkomende medicatiefouten en risicosituaties
In totaal zijn er 121 clinical rules geformuleerd met een brede farmacotherapeutische omvang. 
ADEAS is vervolgens gevalideerd om te controleren of het systeem de situatie beschreven in 
de clinical rule correct detecteert. Met andere woorden of het systeem geen vals positieve of 
vals negatieve signalen genereert. Er was geen standaard validatieprogramma beschikbaar, 
waardoor we zelf een validatieprogramma hebben ontwikkeld. De validatie is uitgevoerd op 
drie manieren: 1) door gebruik te maken van dummypatiënten in het EVS, 2) door ADEAS 
te testen in een offline testomgeving, en 3) door ADEAS achter de schermen te laten draaien 
en de signalen handmatig te controleren met de klinische gegevens van de patiënten.
De ontwikkeling en validatie hebben veel tijd in beslag genomen maar uiteindelijk is het 
gelukt om ADEAS te ontwikkelen als klinisch beslissingsondersteunend systeem voor de 
ziekenhuisapotheek.
Klinische validiteit
Om te onderzoeken of ADEAS ook daadwerkelijk relevante risicosituaties, dus patiënten 
met een risico op een ADE opspoort, is ADEAS vergeleken met andere methodes om 
patiënten met een ADE op te sporen. In hoofdstuk 3 is eerst een proof-of-principle test 
uitgevoerd. In dit onderzoek zijn 13 clinical rules in ADEAS aangezet en zijn gedurende 
drie dagen de veiligheidssignalen die door ADEAS werden gegenereerd verzameld bij alle 




signalen die de arts ziet tijdens het voorschrijven van medicatie afkomstig van de standaard 
medicatiebewaking in het EVS gedurende dezelfde periode.  Hieruit bleek dat met ADEAS 
additionele patiënten met een risico op een ADE werden gedetecteerd.
In hoofdstuk 4 is ADEAS opnieuw vergeleken met de standaard medicatiebewaking in 
het EVS in twee onderzoeken, een retrospectieve en een prospectieve vergelijking. In het 
retrospectieve onderzoek werden alle 121 clinical rules in ADEAS geactiveerd en draaide 
het systeem gedurende één maand op alle patiënten opgenomen in het ziekenhuis (behalve 
de patiënten op de Intensive Care). ADEAS genereerde in die periode 2010 signalen. De 
standaard medicatiebewaking genereerde in dezelfde periode 2322 signalen. Voor het 
prospectieve onderzoek haalde ADEAS alleen gegevens op van de patiënten die waren op-
genomen op een algemene interne geneeskunde afdeling. Dit onderzoek werd gedurende zes 
maanden uitgevoerd. De signalen werden dagelijks vergeleken met de signalen afkomstig 
van de standaard medicatiebewaking. Daarnaast gaf de ziekenhuisapotheker ook adviezen 
aan de arts of verpleging in navolging op een signaal. ADEAS genereerde gedurende deze 
zes maanden 248 signalen tegenover 177 signalen met de standaard medicatiebewaking. 
Veertien keer werd er door de ziekenhuisapotheker een interventie gedaan in navolging 
op een signaal vanuit ADEAS en vijf keer naar aanleiding van een signaal afkomstig van 
de standaard medicatiebewaking. Het soort mogelijke ADE dat met ADEAS bij patiënten 
wordt gedetecteerd is anders dan het soort mogelijke ADE wat wordt gedetecteerd met de 
standaard medicatiebewaking. De standaard medicatiebewaking geeft signalen bij overdo-
seringen en geneesmiddelinteracties. ADEAS geeft vooral signalen bij patiënten met een 
verminderde nierfunctie die een geneesmiddel gebruiken waarvan de dosis afhankelijk is 
van de nierfunctie en bij afwezigheid van noodzakelijke comedicatie.
In het onderzoek dat wordt beschreven in hoofdstuk 5 is de werking van ADEAS vergeleken 
met handmatige medicatiebeoordeling door statusonderzoek. Deze laatste methode is een 
veel gebruikte manier om ADEs op te sporen. Zestien clinical rules in ADEAS werden geacti-
veerd en de signalen vanuit ADEAS werden vergeleken middels handmatig statusonderzoek 
met de gevonden medicatiefouten (o.a. overdoseringen en geneesmiddelinteracties). ADEAS 
detecteerde 39% van de therapeutische medicatiefouten. Wanneer standaard medicatiebe-
waking in het EVS en ADEAS werden gecombineerd werd 66% van de overdoseringen en 
therapeutische medicatiefouten gedetecteerd.
De resultaten van de onderzoeken met betrekking tot de klinische validiteit laten zien dat 
ADEAS in staat is relevante patiënten met een risicosituatie op te sporen en dat ADEAS 
ten opzichte van de standaard medicatiebewaking in het EVS additionele patiënten met een 




Het uiteindelijke doel van de ontwikkeling van ADEAS is medicatieveiligheid en voorkomen 
van ADEs en schade door geneesmiddelengebruik bij de patiënt. In hoeverre medicatie-
bewaking met ADEAS gevolgd door interventies door de ziekenhuisapotheker ADEs kan 
voorkomen of verminderen wordt beschreven in hoofdstuk 6 en hoofdstuk 7.
Hoofdstuk 6 beschrijft een onderzoek waarin voor en na de implementatie van ADEAS 
het aantal ADEs wordt onderzocht door middel van statusonderzoek bij de oudere in het 
ziekenhuis opgenomen patiënt (> 65 jaar) met polyfarmacie (> 5 geneesmiddelen). Voor de 
implementatie van ADEAS werd alleen gebruik gemaakt van medicatiebewaking in het EVS. 
Na de implementatie van ADEAS werden beide systemen gecombineerd; ADEAS en standaard 
medicatiebewaking. Het ADEAS-systeem draaide elke ochtend en genereerde signalen in de 
ziekenhuisapotheek. Vervolgens bekeek de ziekenhuisapotheker deze signalen en zocht rele-
vante informatie op over de patiënt in het elektronisch patiëntendossier en gaf indien nodig 
advies aan de arts of verpleging om een mogelijke ADE te voorkomen. Retrospectief werden 
de statussen van de geïncludeerde patiënten handmatig nagezocht op ADEs. De gevonden 
ADEs werden onderverdeeld in potentieel wel of niet vermijdbaar. In de periode voor gebruik 
van ADEAS werden er middels statusonderzoek 42 vermijdbare ADEs gevonden in een groep 
van 240 patiëntenopnames en na de in gebruik name van ADEAS werden er middels status-
onderzoek nog 27 vermijdbare ADEs in een groep van 248 patiëntenopnames gevonden. Dit 
betekent een relatieve risicoreductie van 37%. Zoals elk onderzoek heeft ook dit onderzoek 
zijn beperkingen. Bij onderzoek naar ADEs worden er altijd kritische vragen gesteld over de 
opzet van het onderzoek, de vergelijkbaarheid van de twee groepen patiënten, eventuele bias 
en de validiteit van de detectiemethode. Desondanks laat dit onderzoek zien dat met ADEAS 
gestuurde interventies door de ziekenhuisapotheker een reductie in ADEs kan worden be-
werkstelligd ten opzichte van het gebruik van alleen medicatiebewaking in het EVS.
Hoofdstuk 7 beschrijft de ervaringen met het dagelijks gebruik van ADEAS in de zieken-
huisapotheek en geeft een berekening van de effectiviteit en de positief voorspellende waarde 
van de clinical rules. Gedurende vijf maanden genereerde ADEAS 2650 signalen bij totaal 
931 in het ziekenhuis opgenomen patiënten. Bij 270 signalen (10%) nam de ziekenhuisapo-
theker contact op met de arts of verpleging en bij 204 signalen gaf de ziekenhuisapotheker 
daadwerkelijk een advies om een ADE te voorkomen. De effectiviteit van de clinical rules is 
berekend door het aantal signalen wat heeft geleid tot een overleg met de arts of verpleging 
te delen door het totaal aantal signalen. Dit resulteerde in een waarde van 0,10. De positief 




geleid tot een advies te delen door het totaal aantal signalen. Dit resulteerde in een waarde 
van 0,08. De meeste signalen werden gegeneerd door clinical rules behorende tot de twee 
risicocategorieën betreffende de combinatie van geneesmiddel en laboratoriumwaarde van 
de patiënt (risicocategorie 1 en 2). De clinical rule effectiviteit en positief voorspellende 
waarde waren het grootst voor clinical rules behorende tot de risicocategorie 5 ‘standaard 
geneesmiddelinteracties uit het EVS aangepast aan risicopatiënten’. Deze beslisregels hadden 
een effectiviteitwaarde van 0,17 en een positief voorspellende waarde van 0,14.
Uit het onderzoek beschreven in hoofdstuk 7 kan geconcludeerd worden dat ADEAS goed 
gebruikt kan worden in de dagelijkse praktijk van de ziekenhuisapotheek, maar dat de inhoud 
van de clinical rules moet worden geoptimaliseerd zodat de effectiviteitwaarde en positief 
voorspellende waarde verhoogd kunnen worden.
Algemene discussie
In het laatste deel, in hoofdstuk 8, worden de resultaten van het in dit proefschrift beschre-
ven onderzoek kritisch besproken en wordt een toekomstvisie over het gebruik van clinical 
rules in de ziekenhuisapotheek gepresenteerd.
De ontwikkeling van ADEAS is succesvol, maar achteraf kan geconcludeerd worden dat de 
uitgebreide set beslisregels met een brede farmacotherapeutische dekkingsgraad niet de beste 
manier was om te beginnen. Een kleinere set clinical rules beperkt tot de risicocategorieën 
1, 2 en 5 zou beter geweest zijn, omdat deze clinical rules het meest effectief zijn en met een 
beperkte set beslisregels het validatieproces minder tijdrovend was geweest.
De meerwaarde van ADEAS komt vooral tot uiting in de mogelijkheid om ook de labora-
toriumwaarden te betrekken bij het opsporen van patiënten met een mogelijke ADE. Dit is 
niet mogelijk met de standaard medicatiebewaking in het EVS. Daarnaast houdt ADEAS 
ook rekening met de comedicatie van de patiënt, iets wat de standaard medicatiebewaking 
niet kan doen. Voorbeelden van nuttige veiligheidssignalen die werden gegenereerd aan de 
hand van clinical rules zijn: 1) het vergeten van laboratoriumcontrole van de vancomyci-
neconcentratie in het bloed bij het gebruik van vancomycine, 2) een te hoge dosis van een 
geneesmiddel bij een patiënt met een verminderde nierfunctie en 3) het ontbreken van een 
laxans bij langdurig opiaatgebruik. ADEAS geeft signalen bij dergelijke risicosituaties en 
kan zo bijdragen schade bij de patiënt te voorkomen. Dit in tegenstelling tot computersys-
temen die pas signalen geven als de patiënt al schade heeft ondervonden, bijvoorbeeld bij 
het voorschrijven van een antidotum om de effecten van een overdosering tegen te gaan.
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Voor toekomstig gebruik is het belangrijk dat de effectiviteit en positief voorspellende waarde 
van de clinical rules wordt geoptimaliseerd. Op dit moment zijn er nog te veel signalen waarbij 
uiteindelijk geen actie nodig is. ADEAS genereert bijvoorbeeld een signaal bij de risicosituatie 
ciprofloxacinegebruik bij een verminderde nierfunctie. De ziekenhuisapotheker controleert de 
dosering, maar er is geen actie nodig, want de arts heeft de dosering correct aangepast. Zo’n 
signaal leidt dus uiteindelijk niet tot een interventie. In de toekomst kan de clinical rule geop-
timaliseerd worden door het item dosering toe te voegen als selectiecriterium in de beslisregel.
Op dit moment wordt ADEAS alleen gebruikt in de ziekenhuisapotheek. Als in de toekomst de 
signalen uit ADEAS rechtsreeks bij de arts terecht komen is het belangrijk dat het percentage 
niet klinisch relevante signalen laag is, want anders bestaat het risico op signaalmoeheid. Dat 
betekent dat er te veel onnodige veiligheidssignalen aan de arts getoond worden en de signalen 
niet meer gelezen worden met de consequentie dat de wel relevante signalen ook gemist worden. 
In de toekomst zien wij drie verschillende mogelijke toepassingen voor clinical rules:
1.  Beslisregels als dagelijkse medicatiebewaking voor de ziekenhuisapotheker.
2. Beslisregels als dagelijkse medicatiebewaking direct tijdens het voorschrijven 
zichtbaar in het EVS voor de arts. Deze clinical rules selecteren risicosituaties 
waarbij direct actie nodig is en geen vertraging gewenst is.
3. Beslisregels die gebruikt kunnen worden voor een periodieke medicatiere-
view door de ziekenhuisapotheker.
Daarnaast moeten we energie steken in het integreren van ADEAS en de standaard medi-
catiebewaking, op dit moment nog twee afzonderlijke systemen. Verder vergt de borging 
van de kwaliteit van ADEAS en het up-to-date houden van het systeem onze aandacht. En 
niet te vergeten de klinische activiteiten van de ziekenhuisapotheker op de verpleegafdeling; 
deze moeten in de toekomst vergroot worden.
ADEAS is een eigen ontwikkeld klinisch beslissingsondersteunend systeem voor de zieken-
huisapotheek. Het LUMC is een van de eerste ziekenhuizen die dit concept heeft toegepast. 
Dit proefschrift kan bijdragen aan een verder optimaal gebruik van clinical rules in de 
Nederlandse ziekenhuisfarmacie. Zowel binnen de Nederlandse Vereniging van Ziekenhuis-
apothekers (NVZA) en de Koninklijke Nederlandse Maatschappij ter bevordering van de 
Pharmacie (KNMP) wordt het belang van het gebruik van clinical rules onderschreven. In 
de toekomst zijn clinical rules niet weg te denken uit de praktijk van de ziekenhuisapotheek 
en zullen zij bijdragen aan een optimaal gebruik van geneesmiddelen en het bevorderen 
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